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Pediatric renal transplantation (TX) has evolved greatly during the past 
few decades, and today TX is considered the standard care for children 
with end-stage renal disease. In Finland, 191 children had received renal 
transplants by October 2007, and 42% of them have already reached 
adulthood. Improvements in treatment of end-stage renal disease, surgical 
techniques, intensive care medicine, and in immunosuppressive therapy 
have paved the way to the current highly successful outcomes of pediatric 
transplantation. In children, the transplanted graft  should last for decades, 
and normal growth and development should be guaranteed. Th ese 
objectives set considerable requirements in optimizing and fi ne-tuning 
the post-operative therapy. Careful optimization of immunosuppressive 
therapy is crucial in protecting the graft  against rejection, but also in 
protecting the patient against adverse eff ects of the medication.
In the present study, the results of a retrospective investigation into 
individualized dosing of immunosuppresive medication, based on 
pharmacokinetic profi les, therapeutic drug monitoring, graft  function and 
histology studies, and glucocorticoid biological activity determinations, 
are reported. Subgroups of a total of 178 patients, who received renal 
transplants in 1988–2006 were included in the study. Th e mean age at 
TX was 6.5 years, and 26% of the patients were <2 years of age. Th e most 
common diagnosis leading to renal TX was congenital nephrosis of the 
Finnish type (NPHS1).   
Pediatric patients in Finland receive standard triple immunosuppression 
consisting of cyclosporine A (CsA), methylprednisolone (MP) and 
azathioprine (AZA) aft er renal TX. Optimal dosing of these agents 
is important to prevent rejections and preserve graft  function in one 
hand, and to avoid the potentially serious adverse eff ects on the other 
hand. CsA has a narrow therapeutic window and individually variable 
pharmacokinetics. Th erapeutic monitoring of CsA is, therefore, mandatory. 
Traditionally, CsA monitoring has been based on pre-dose trough levels 
(C0), but recent pharmacokinetic and clinical studies have revealed that 
the immunosuppressive eff ect may be related to diurnal CsA exposure 
and blood CsA concentration 0–4 hours aft er dosing. Th e two-hour post-
dose concentration (C2) has proved a reliable surrogate marker of CsA 
exposure. 
Individual starting doses of CsA were analyzed in 65 patients. A 
recommended dose based on a pre-TX pharmacokinetic study was 
calculated for each patient by the pre-TX protocol. Th e predicted dose was 
clearly higher in the youngest children than in the older ones (22.9±10.4 
and 10.5±5.1 mg/kg/d in patients <2 and >8 years of age, respectively). 
Th e actually administered oral doses of CsA were collected for three weeks 
aft er TX and compared to the pharmacokinetically predicted dose. Aft er 
the TX, dosing of CsA was adjusted according to clinical parameters and 
blood CsA trough concentration. Th e pharmacokinetically predicted dose 
and patient age were the two signifi cant parameters explaining post-TX 
doses of CsA. Accordingly, young children received signifi cantly higher 
oral doses of CsA than the older ones. Th e correlation to the actually 
administered doses aft er TX was best in those patients, who had a predicted 
dose clearly higher or lower (> ±25%) than the average in their age-group. 
Due to the great individual variation in pharmacokinetics standardized 
dosing of CsA (based on body mass or surface area) may not be adequate. 
Pre-Tx profi les are helpful in determining suitable initial CsA doses.
CsA monitoring based on trough and C2 concentrations was analyzed 
in 47 patients, who received renal transplants in 2001–2006. C0, C2 
and experienced acute rejections were collected during the post-TX 
hospitalization, and also three months aft er TX when the fi rst protocol 
core biopsy was obtained. Th e patients who remained rejection free had 
slightly higher C2 concentrations, especially very early aft er TX. However, 
aft er the fi rst two weeks also the trough level was higher in the rejection-
free patients than in those with acute rejections. Th ree months aft er TX 
the trough level was higher in patients with normal histology than in 
those with rejection changes in the routine biopsy. Monitoring of both the 
trough level and C2 may thus be warranted to guarantee suffi  cient peak 
concentration and baseline immunosuppression on one hand and to avoid 
over-exposure on the other hand.
Controlling of rejection in the early months aft er transplantation is 
crucial as it may contribute to the development of long-term allograft  
nephropathy. Recently, it has become evident that immunoactivation 
fulfi lling the histological criteria of acute rejection is possible in a well 
functioning graft  with no clinical sings or laboratory perturbations. Th e 
infl uence of treatment of subclinical rejection, diagnosed in 3-month 
protocol biopsy, to graft  function and histology 18 months aft er TX was 
analyzed in 22 patients and compared to 35 historical control patients. 
Th e incidence of subclinical rejection at three months was 43%, and the 
patients received a standard rejection treatment (a course of increased 
MP) and/or increased baseline immunosuppression, depending on the 
severity of  rejection and graft  function. Glomerular fi ltration rate (GFR) at 
18 months was signifi cantly better in the patients who were screened and 
treated for subclinical rejection in comparison to the historical patients 
(86.7±22.5 vs. 67.9±31.9 ml/min/1.73m2, respectively) . Th e improvement 
was most remarkable in the youngest (<2 years) age group (94.1±11.0 
vs. 67.9±26.8 ml/min/1.73m2). Histological fi ndings of chronic allograft  
nephropathy were also more common in the historical patients in the 18-
month protocol biopsy. 
All pediatric renal TX patients receive MP as a part of the baseline 
immunosuppression. Although the maintenance dose of MP is very low in 
the majority of the patients, the well-known steroid-related adverse aff ects 
are not uncommon. It has been shown in a previous study in Finnish 
pediatric TX patients that steroid exposure, measured as area under 
concentration-time curve (AUC), rather than the dose correlates with the 
adverse eff ects. In the present study, MP AUC was measured in sixteen 
stable maintenance patients, and a correlation with excess weight gain 
during 12 months aft er TX as well as with height defi cit was found. A novel 
bioassay measuring the activation of glucocorticoid receptor – dependent 
transcription cascade was also employed to assess the biological eff ect 
of MP. Glucocorticoid bioactivity was found to be related to the adverse 
eff ects, although the relationship was not as apparent as that with serum 
MP concentration.
Th e fi ndings in this study support individualized monitoring and 
adjustment of immunosuppression based on pharmacokinetics, graft 
function and histology. Pharmacokinetic profi les are helpful in estimating 
drug exposure and thus identifying the patients who might be at risk for 
excessive or insuffi  cient immunosuppression. Individualized doses and 
monitoring of blood concentrations should defi nitely be employed with 
CsA, but possibly also with steroids. As an alternative to complete steroid 
withdrawal, individualized dosing based on drug exposure monitoring 
might help in avoiding the adverse eff ects. Early screening and treatment 
of subclinical immunoactivation is benefi cial as it improves the prospects 
of good long-term graft  function.
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GR Glucocorticoid receptor
HLA Human leucocyte antigen
LRD Living related donor
MCH Major histocompatibility complex
MMF Mycophenolate mofetil
MP Methylprednisolone
P-Crea Plasma creatinine concentration
PRA Panel reactive antibodies
PTLD Post-transplant lymphoproliferative disorder
Tac Tacrolimus
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Organ transplantation (TX) has greatly changed the course of many 
diseases that previously lead to death aft er long, agonizing periods of 
treatments. During the past three decades kidney transplantation has 
become a highly successful treatment for children with end-stage renal 
disease (ESRD). Renal replacement therapy became applicable to children 
on routine basis in the late 1960s, but complications cast a shadow over 
the prospects of children with ESRD for years. Renal replacement therapy 
remained controversial in pediatric patients until the early 1980s, as 
expressed in a medical textbook on renal disease in 1979  “…we cannot 
escape the question whether children with end-stage renal failure should 
be treated or helped to die peacefully…”, “…treating children under the 
age of 5…we do not always recommend…”, and the prevailing treatment 
“…justifi ed the hope that a substantial number of patients should survive 
10–20 years and live a useful life” [1]. 
Kidney TX has proved a superior treatment for children with ESRD 
in comparison with long-term dialysis [2–6]. Today, more than 80% of 
children with renal transplants are expected to survive into adulthood 
[7–14]. Outcomes of organ TX have improved markedly over the past 
20 years, mainly due to advances in surgical techniques, suitable choice 
of donors and recipients, better control of complications, and striking 
developments in immunosuppressive therapy. Most notable clinical 
advance in immunosuppression was the discovery of cyclosporine A [15] 
and its introduction in pediatric TX in the mid 1980s [16–18]. Th e primary 
aim of immunosuppression is to prevent acute and chronic rejection but 
it is essential that the aim is compatible with good quality of life. Organ 
transplant recipients are confronted with life-long immunosuppressive 
therapy with potentially serious adverse eff ects, e.g. nephrotoxicity, growth 
inhibition, increased risk for metabolic and cardiovascular disturbances, 
infections and malignancies. Th e pediatric patients continue to receive 
immunosuppressive medication for decades, which emphasizes the 
importance of optimal drug therapy. 
Many immunosuppressive drugs in clinical TX share certain basic 
features, such as considerable interindividual variability in dosing 
requirements and relatively narrow therapeutic window, thus requiring 
therapeutic drug monitoring [19, 20]. Th erapeutic protocols in children 
are oft en modifi ed from those used in adults, although there are many 
fundamental diff erences in metabolism and pharmacokinetics in the 
growing and developing recipient [21]. Individualized immunosuppression 
with continuous monitoring and timely modifi cation of therapy is 
imperative for successful long-term outcome in pediatric TX. 
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5. REVIEW OF THE LITTERATURE
5.1 Renal transplantation in children
Th e incidence of ESRD varies between 5–10 children per million [22], 
and with improving survival and availability of treatment, the number of 
children receiving renal replacement therapy is increasing. Kidney TX is the 
optimal treatment for ESRD, leading to substantial improvement in quality 
of life. It is the consensus opinion that dialysis and/or renal TX should 
be considered for children when the glomerular fi ltration rate (GFR) falls 
below 15 ml/min/1.73m2 [23–25]. Etiology of ESRD in children diff ers from 
that in adults, so that congenital lesions such as obstructive uropathy and 
renal aplasia/dysplasia, together with focal segmental glomerulosclerosis 
(FSGS) account for nearly half of the transplants in the North America. 
Th e diagnostic categories listed for the indication for renal TX, according 
to the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS), are displayed in Table 1. However, diff erences exist in the 
incidence of various diseases among countries. Chronic glomerulonephritis 
is a common cause (approximately 40%) for ESRD in developing countries. 
In Europe, hereditary familial nephropathies are reported three times more 
frequently than in the developing world. In Finland, congenital nephrotic 
syndrome of the Finnish type (CNF) accounts for nearly a half of renal TX in 
children, while in Sweden nephronophthisis is the most common singular 
cause, representing 20% of pediatric renal transplantation [26, 27]. 
Renal TX in children is oft en considered contraindicated in cases of 
severe neurological disease. In cases of concomitant infectious disease, 
active and rapidly progressed renal disease (e.g. hemolytic syndrome or 
crescentic glomerulonephritis) or malignancy, renal TX should be delayed 
until the underlying disease is controlled. Abnormalities in the urinary 
tract should be detected and corrected before TX. In some children with 
chronic kidney disease, it may be appropriate to perform TX before dialysis 
is needed (pre-emptive transplantation), thus improving the quality of life 
for these children, and perhaps improving the prognosis of the graft  [28]. 
However, most children are on dialysis, either peritoneal or hemodialysis, 
prior to TX [29]. Pre-emptive TX is oft en performed from a living related 
donor (LRD), usually a parent [30]. Using a LRD transplant, timing of the 
operation can be decided in advance, thus shortening the waiting time on 
dialysis and limiting the related complications. Th e long-term results of 
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LRD kidney TX have been somewhat better than with a deceased donor 
(CAD). At the end of the last decade, the 1 – , 3 – , and 5 – year graft  survival 
rates were 95, 90 and 83% using LRD, respectively, and 91, 82 and 75% in 
CAD transplantations [9]. However, the graft  survival rates are improving 
for both donor types, and the diff erence between the two is narrowing 
[30–32]. Th e proportion of LRD in pediatric TX varies greatly from one 
country to another, from 86% in Scandinavia (excluding Finland) and 
52% in USA, to less than 10% in France. Factors explaining the diff erences 
include activity of the cadaver transplant programs, the criteria for organ 
allocation to children, the way the parents are provided information about 
LRD and CAD transplantation, and cultural diff erences. 
Apart from donor source, other risk factors for successful renal TX in 
children include recipient age, donor age, race (black vs. non-black), number 
of histocompatibility antigen mismatches, long cold-ischemia time (>24 
hours), re-transplantations and prior blood transfusions, and the level of 
panel reactive antibodies (PRA). Th e number of pediatric deceased donors 
has decreased slowly over the decade. According to the US registry, 14% of 
kidney donors were under 18 years of age in 2004 [32]. Young deceased donor 
age (≤5 years) has been considered a risk factor for graft  failure, although 
the results with graft s from very young donors are constantly improving 
[31]. Also, young recipient age (<24 months) may involve increased risk 
of graft  failure because of greater immune reactivity and enhanced risk for 
graft  thrombosis [33]. Prior transplantation, more than fi ve life-time blood 
transfusions, black race and mismatches in the human leukocyte antigen 
(HLA) system all add to the risk of graft  failure [30].
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Table 1. Incidence of the most common diseases leading to renal transplantation in 





Focal segmental glomerulosclerosis 12
Refl ux nephropathy 5
Chronic glomerulonephritis 3
Polycystic kidney disease 3
Medullary cystic disease 3
Hemolytic uremic syndrome 3
Brune Belly 3
Congenital nephrotic syndrome 3
Cystinosis 2
Pyelo/interstitial nephritis 2
Membranoproliferative glomerulonephritis type I 2
Other or unknown 27
5.1.1 Pediatric renal transplantation in Finland
Pediatric renal TX program began in Finland in the mid 1980s, and by 
October 2007 191 children had received kidney transplants. One or more 
re-TX have been performed in 15 patients, and the number of kidney TX 
operations in children exceeds 200. Overall patient survival is 96%. Th e 
short-term patient and graft  survival approaches 100%, and also the long-
term outcome aft er renal TX in childhood is encouraging [34, 35]. Seventy-
four (42%) patients who received a kidney transplant in childhood have 
reached adulthood.
Th e most common cause leading to ESRD in Finland is CNF, which 
results from mutations in NPHS1 gene encoding nephrin, a transmembrane 
cell adhesion protein located in the podocyte slit diaphragm of kidney 
glomerulus [36]. Two mutations, Fin-major and Fin-minor, account for 
more than 90% of mutations in Finland [37], and are rare in non-Finnish 
patients [38]. Several other genes have also been implicated in nephrotic 
syndrome worldwide [39]. Mutations in NPHS1 lead to massive proteinuria 
with secondary complications. In order to minimize the complications, 
these patients are bilaterally nephrectomized and dialyzed from an early age 
(<1 year). Continuous cycling peritoneal dialysis is used almost exclusively 
in the Finnish patients [40]. Seventy-two children in Finland have received 
kidney transplants because of CNF (38% of all pediatric renal TX patients), 
and 49 (68%) of them were under two years of age at the time of TX. 
Other causes leading to renal TX in Finland include urtheral valve (12%), 
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nephronophthisis (8%), polycystic kidneys (7%), glomerulonephritis (6%) 
and dysplastic kidneys (5%). 
 Young recipient age has been considered a risk factor for graft  failure 
because of enhanced immunological reactivity and increased risk for graft  
thrombosis [41]. In addition to surgical complications acute tubular necrosis 
(ATN) is risk factor for arterial and venous thrombosis [42], and it is a more 
frequent complication in CAD than LRD TX [30]. Th erefore, LRD TX has 
been advocated especially in young children. Because of the high incidence 
of CNF, a notable number of kidney TX patients are under two years of age 
in Finland. A third of pediatric recipients in Finland have received a LRD 
kidney, and 43% of them were ≤2 years of age. Th e incidence of rejection 
in the youngest patients in Finland does not appear to exceed that in the 
older patients [43], and graft  thrombosis is an uncommon complication 
[44]. However, the long-term graft  function in patients transplanted at an 
age less than two years, has not been as favorable as in the older children 
[45]. Th e reasons for the diff erence are not fully understood, but it has 
been postulated that the hemodynamic conditions in infants would not 
support suffi  cient arterial fl ow to an adult-sized graft  [46]. Th erefore, 
larger volumes of maintenance fl uids have been suggested for the youngest 
patients to prevent chronic hypoperfusion of the graft  [47].  
An important aspect of care aft er transplantation is the child’s growth. 
Improvement in patient care prior to TX has resulted in diminishing 
height defi cit at the time of TX, which is an important determinant of 
fi nal height. Long-term graft  function as well as glucocorticoid therapy are 
other signifi cant factors infl uencing growth [48]. In Finland, growth aft er 
renal TX in pediatric patients has been satisfactory, although not optimal 
[49, 44]. Declining graft  function, especially in the youngest age group 
(<2 years) correlates with suboptimal catch-up growth, but glucocorticoid 
therapy inevitably aff ects growth as well. Th e use of glucocorticoids, 
although with tapering doses, is also related to excessive weight gain, which 
is a rather common problem aft er renal TX in Finland [44]. Disturbances 
in serum cholesterol and triglyceride concentrations are also rather 
common, although very mild in majority of the patients [50]. All pediatric 
renal TX patients in Finland receive triple immunosuppression consisting 
of cyclosporine A (CsA), azathioprine (AZA) and methylprednisolone 
(MP). Modifi cations of the standard protocol are made individually, when 
clinically required.
5.2 Transplant immunology
Th e success of organ TX is primarily limited by allograft  rejection, an 
intrinsic part of the immune defense diff erentiating self from non-self, and 
protecting the organism from invaders. Only graft s between individuals 
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of the same genetic composition (syngeneic) are accepted, whereas graft s 
across these genetic barriers (allogeneic) are rejected. 
Antigens encoded by the genes of the major histocompatibilty complex 
(MHC) on the short arm of chromosome 6, play a singular role in acting 
as major stimulants and targets of graft  rejection. Th e MHC encodes cell 
surface protein molecules (MHC antigens), which in man are referred as 
the human leucocyte antigens (HLA). MHC is physically grouped into 
three regions – the class I and II regions (MHC-I and MHC-II) include 
the important histocompatibility loci, which encode the heavy chains of 
the HLA-A, -B and -C, and alpha and beta chains of the HLA-DR, -DP and 
-DQ molecules, respectively. Th e class III region encodes components of 
the complement pathway, among others. 
Most nucleated cells express MHC-I antigens, which bind peptides 
generated through an endogenous pathway. A healthy cell supplies 
a suffi  cient representation of self-peptides displayed by the MHC-I 
molecule. A cell invaded by an intracellular pathogen produces MHC-I / 
foreign peptide complexes on its surface, signaling infection. Th e MHC-I 
/ peptide complexes on the cell surface are then accessible for detection 
by T-cell or natural killer (NK) cell receptors. Th e MHC-II antigens, on 
the other hand, bind peptides generated through an exogenous pathway, 
and they are characteristic of B-lymphocytes, macrophages, dendritic cells, 
Langerhans cells, thymic epithelial cells and activated T-cells. Th ese so-
called “antigen-presenting cells” (APC) continually sample molecules from 
the extracellular space and introduce fragments of these on the cell surface 
in MHC-II / peptide complexes, where they are accessible for interaction 
with T-cell receptors (TCR) [51]. 
5.2.1 Allorecognition
Following transplantation of allogenic tissues, recognition by recipient 
T-lymphocytes of foreign proteins and peptides (T-cell allorecognition) 
initiates a cascade of immunological reactions resulting in rejection 
of the graft . Th is process is mediated via two distinct but non-exclusive 
mechanisms, the direct and indirect allorecognition pathway (Figure 
1). Th e direct pathway represents a polyclonal T-cell response initiated 
via the presentation of allogenic MHC molecules by donor passenger 
leucocytes in the recipient’s lymphoid organs. Th e multiplicity and high 
density of determinants created by the presence of allo-MHC on APCs 
results in enormous frequency of activated T-cells. Direct allorecognition 
is responsible for early sensitization of the host to donor antigens, 
leading to acute graft  rejection. In contrast, self-MHC restricted indirect 
allorecognition (recipients own APC’s) is oligoclonal and generally limited 
to few dominant allodeterminants, which, however may alter with time. Th e 
direct type response diminishes with time, whereas indirect alloresponses 
persist and seem to correlate with the chronic rejection process [52, 53]. 
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Figure 1. CD4+ T-cells recognize antigen through direct and indirect pathways, 
become activated, and undergo clonal proliferation. Activated CD4+ T-cells provide 
help for monocyte/macrophages, B-cells, and cytotoxic CD8+ T-cells by secreting 
cytokines and by cell-cell contact dependent mechanisms. Activated monocytes/
macrophages release a range of noxious agents that mediate tissue injury. B-cell 
alloantibody production ultimately results in complement mediated tissue destruction. 
Activated CD8+ T cells kill graft  cells in antigen-specifi c manner through induction of 
apoptosis and cell lysis. (Adapted from Denton et al [54]).
5.2.2 Mechanisms of allograft rejection
Th e anti-allograft  response is contingent on the coordinated action of 
alloreactive T-cells and APCs, achieved through an elaborate network 
of cell surface receptor – ligand interactions. Naive lymphocytes are not 
programmed for a particular eff ector response nor do they recognize 
soluble forms of antigens. Th e initiation of rejection requires that foreign 
antigens are presented in association with MHC molecules on the surface 
of APCs, including macrophages, activated B-cells and the professional 
APCs, dendritic cells. Th rough the release of cytokines and cell-to-cell 
interactions, a diverse assembly of CD4+ helper T-cells, CD8+ cytotoxic 
T-cells, antibody-forming B-cells, and other proinfl ammatory leucocytes 
are recruited into the response. Th e repertoire of T-cells involved in 
allorecognition include CD4+ T-cells, which recognize donor MHC-II 
via the direct pathway, and those that are sensitized indirectly by donor 
peptides bound to self-MHC-II on recipient APCs. Some CD8+ T-cells 
directly recognize donor MHC-I peptides while another subset is cross-
presented of processed antigens by recipient APCs in the context of 
MHC-I peptides [55]. Each T-lymphocyte clone has a unique TCR, which 
confers the cell the capability of binding to suitable ligand or antigen in 
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a MCH-specifi c manner. TCR is also bound to the CD3 surface protein, 
which initiates the signal transduction cascade aft er TCR-MHC peptide 
interaction [56]. Th e APC – T-cell interaction does not always result in 
T-cell activation, but costimulation by a class of cell surface molecules with 
no independent stimulatory capacity is required to allow full activation of 
naive lymphocytes [57, 58, 59]. Th e most signifi cant costimulatory signals 
are the B7 – CD28 and CD40 – CD154 interactions [60]. 
Th ree potential eff ector mechanism have been implicated in allograft  
rejection: the production of cytokines and cytotoxic enzymes by CD4+ 
helper T-cells (Th ) and CD8+ cytolytic T-cells (CTL), respectively, and 
promotion of production of alloreactive antibodies. CD4+ T-cells can 
contribute to rejection by providing signals (e.g. interleukin-2) that promote 
CTL activity of CD8+ T-cells, or by activating dendritic cells to promote 
CTL diff erentiation. Th ey also provide signals that promote diff erentiation 
and activation of alloantibody-producing B-cells, or activation of antigen-
independent eff ector leucocytes (delayed-type hypersensitivity reaction). 
Activated Th -cells can be segregated into Th 1 and Th 2 on the basis of their 
cytokine secretion. Interferon -γ (IFN-γ) and lymphotoxin are characteristic 
of Th 1-cells, which enhance cell-mediated immunity, delayed-type 
hypersensitivity reactions, and auto-immune diseases. Typical cytokines 
of Th 2-cells are interleukin (IL) -4, IL-10 and IL-13, which promote 
humoral and allergic responses. In an oversimplifi ed view, Th 1-cells are 
thought to be more responsible for allograft  rejection, whereas Th 2-cells 
may cause anergy and reduce the risk of rejection. However, Th 2 cytokines 
are not essential for prolonged graft  survival, and immunity driven either 
by Th 1 or Th 2 is damaging to the graft . Activated CD8+ T-cells damage 
graft s primarily by direct cytolysis of parenchymal or vascular cells bearing 
antigens that are recognized by the TCR of CTL’s. Perforin and granzyme 
A and B represent molecular mediators of the lytic activity, while contact-
dependent activation of the FasL pathway signals apoptotic death of the 
target cell [61, 62]. CD8+ T-cells express chemokine receptors as well as 
secrete a large number of chemokines, thus recruiting other eff ector cells. 
B-cells capture soluble antigens by surface immunoglobulins and process 
them into peptides to be presented within the surface MHC-II molecules. 
Primed Th -cells recognize the MHC-II / peptide complex expressed by 
B-cells and provide costimulatory signals, which enable B-cell activation, 
proliferation and diff erentation [63]. Alloantibodies produced by B-cells 
circulate freely and gain access to graft  tissue, where antibody-coated 
cells can be killed by the activation of the complement cascade or NK-cell 
mediated cytotoxicity [64, 65]. 
Th e activation and proliferation of eff ector T-cells is regulated by a 
number of cell populations. Naturally occurring regulatory T-cells (Treg), 
which emerge from the thymus as a part of normal immunomaturation, 
constitute approximately 1–2% of the CD4+ cell population. Tregs 
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coexpressing CD4+CD25+ and a transcription factor FoxP3 play a crucial 
role in the prevention of organ-specifi c auto-immune disease [66]. Other 
regulatory cell types have also been identifi ed, such as CD8+CD25+ and 
CD8+CD28- T-cells. Although the mechanisms of Tregs is only partly 
understood, it has become evident that these cells not only attenuate 
autoimmune phenomena and suppress tumor growth but also play a 
pivotal role in tolerance towards alloantigens [67, 68]. 
5.2.3 Consequences of allograft rejection
Th e terms acute and chronic rejection describe distinct clinical 
manifestations of the underlying rejection process. Anti-donor antibodies 
present at the time of TX may trigger immediate, hyper-acute rejection, 
which is a well-recognized, devastating antibody-mediated transplant 
injury. Th is form of graft  failure can be largely avoided by pre-TX assessment 
of ABO blood group and anti-HLA antibodies and cross matching. 
Th e immunopathologic injury in acute rejection (AR) is caused by 
T-cells (T-cell-mediated rejection) and antibodies (humoral rejection), 
either alone or together. Acute cellular rejection typically appears during 
the fi rst 1–6 weeks aft er TX but may occur at any time, even aft er many 
years. T-cells infi ltrate the tubulo-interstitium, glomeruli and arteries, 
separately or together. Th e most common form of cellular AR is tubulo-
interstitial rejection, where T-lymphocytes accumulate in the peritubular 
capillaries and in the interstitium causing edema, and infi ltrate the tubule 
walls (tubulitis). Th is results in epithelial cell damage and may disrupt 
the tubular walls. In cell-mediated arterial rejection T-lymphocytes 
accompanied by other leucocytes accumulate in arteries and arterioles 
undermining the endothelium. Arterial cell-mediated rejection may 
accompany tubulo-interstitial AR making the prognosis more ominous [69]. 
Glomerular infl ammation and cellular damage caused by lymphocyte and 
monocyte infi ltration (acute allograft  glomerulopathy) is a very infrequent 
but severe form of cell-mediated rejection, which may be found in the 
absence of tubulo-interstitial AR. In acute humoral rejection antibodies 
are directed against endothelial cells of arteries or peritubular capillaries. 
In humoral arterial AR neutrophils, eosinophils and monocytes infi ltrate 
the arterial wall causing infl ammation and fi brin formation, hemorrhage 
and parenchymal infarction commonly ensue. Th is type of rejection is 
uncommon and associated with poor graft  prognosis. Peritubular capillary 
form of humoral AR may coexist with tubulo-interstitial AR. Th e fi ndings 
vary from peritubular capillary infl ammation to acute tubular cell injury 
or necrosis. A stable breakdown product of complement component C4, 
C4d, binds to the site of rejection and is a characteristic fi nding in this type 
of rejection. 
Chronic allograft  nephropathy (CAN) is an insidious process, 
characterized morphologically by varying degrees of arterial and glomerular 
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lesions, and signifi cant tubular atrophy with interstitial fi brosis. Arteries 
display intimal thickening with fi brosis, accumulation of macrophages and 
foam cells, and calcifi cation. Th e glomerular changes are characterized 
by increase in mesangial matrix and cellularity, and double-contoured 
capillary walls. CAN gradually matures and may not dissipate over time, 
but results in deterioration of graft  function over years, and responds poorly 
to non-specifi c immunosuppressive treatment. In addition to chronic 
rejection, other factors may compound the picture (e.g. viral infections, 
drug-induced injury) and all the insults collectively determine the onset 
and tempo of CAN.
5.2.4 Classifi cation of renal allograft histopathology
From a practical point of view, standardization of allograft  biopsy 
interpretation is necessary. Th e histologic criteria and grading of severity 
of acute and chronic rejection in renal biopsy specimen were defi ned as an 
international consensus statement in the Banff  ‘97 classifi cation [70], and 
updated thereaft er [71, 72]. 
5.2.4.1 Banff classifi cation of acute rejection 
Tubilitis and vasculitis are the cardinal features of rejection. Grading of 
non-atrophic tubules according to number of cells per cross section ranges 
from t0 with no mononuclear cells in tubules to t3 with >10 cells per 
section. Infl ammatory tubular injury and basement membrane destruction 
may be present in t3. Diagnosis of tubulitis requires it to be present in 
more than one focus in the biopsy, and that the most infl amed areas and 
tubules are sought. Likewise, in grading of arteritis, the focus should be 
in the most severely involved vessels. Grading ranges from v0 with no 
lymphocytic infl ammation to v3 with transmural arteritis and/or fi brinoid 
change and smooth muscle necrosis, with accompanying infl ammation 
in the vessel. Interstitial hemorrhage and/or infarction are marked with 
an asterisk added to the score. While not an independent criterion for 
rejection, a background interstitial infl ammation is required for the 
diagnosis of tubulointerstitial rejection. Grading ranges from i0 with no 
infl ammation to i3 with greater than 50% of the parenchyma infi ltrated 
with T-lymphocytes and monocytes/macrophages. Remarkable numbers of 
other cell types are marked with an asterisk, and should evoke diff erential 
diagnoses. Glomerulitis is defi ned by mononuclear cell infi ltrate and 
endothelial cell enlargement. Although not used as criterion for rejection, 
glomerulitis is graded from g0 with normal glomeruli to g3 with mostly 
global (>75%) glomerulitis. Types of acute rejection are categorized as 
Type I, tubulointerstitial rejection without arteritis, and Type II, intimal 
arteritis, and Type III, severe vascular rejection. Mild tubulitis with only 
mild focal interstitial infl ammation is categorized as borderline rejection. 
Th e Banff  ‘97 classifi cation for acute rejection is summarized in Table 2. 
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5.2.4.2 Banff classifi cation of chronic allograft nephropathy
Chronic changes in a renal allograft  biopsy may be seen in glomeruli, 
interstitium, tubules and vessels. Interstitial fi brosis and tubular atrophy are 
non-specifi c fi ndings, that are graded in the Banff  ‘97 classifi cation based 
on the percentage of parenchyma involved. Fibrosis is graded from ci0 with 
<5% to ci3 with >50% in cortical area, and tubular atrophy from ct0 with 
no fi ndings to ct3 with atrophy in >50% of the area of cortical tubules. As a 
specifi c sign of transplant glomerulopathy, the presence of double contours 
in capillary loops, created by mesangial interposition, is graded from cg0 
with <10% to cg3 with >50% of peripheral capillary loops aff ected. As a less 
specifi c fi nding, increase in mesangial matrix between adjacent glomerular 
capillaries is graded from mm0 with no matrix increase to mm3 with >50% 
of glomeruli aff ected. Vascular changes include disruptions of the elastica, 
infl ammatory cells and proliferation of myofi broblasts in the intima, and 
formation of a second “neointima”. Th ese chronic changes are graded from 
cv0 with no fi ndings to cv3 with >50% narrowing of the luminal area. 
Arteriolar hyaline thickening, indicative of calcineurin inhibitor toxicity, is 
graded separately from ah0 with no hyalinosis to ah3 with severe periodic-
acid-Schiff  –positive thickening in many arterioles. Tubular cell injury 
with isometric vacuolization may also be present in CNI toxicity. CAN is 
categorized as CI mild, CII moderate or CIII severe (Table 2). 
Recently, accurate diagnosis of the underlying processes of chronic 
allograft  dysfunction have been emphasized, and also the use of term 
CAN has bee questioned [72]. Chronic conditions such as hypertension, 
calcineurin inhibitor toxicicty, obstructive nephropathy, pyelonephritis 
or viral infections, diabetes and glomerular or vascular disease (recurrent 
or de novo) result in interstitial fi brosis and tubular atrophy, but also to 
recognizable morphological fi ndings, and require specifi c therapies. CNI 
toxicity may occur acutely aft er TX and manifest in declining graft  function. 
Th is is, however oft en reversible aft er modifi cation of therapy. Chronic CNI 
toxicity may be more diffi  cult to distinguish from other forms of chronic 
damage, and it may coexist with rejection and other chronic changes. It is 
also less responsive to dose reduction. Chronic alloimmune injury is an 
important cause of fi brosis and tubular atrophy in the graft . Recent data on 
circulating anti-donor antibodies and capillary-endothelial C4d deposits 
indicates a pathogenic role of humoral immunity in patients with chronic 
allograft  dysfunction. Th e diagnostic criteria for identifi cation of antibody-
mediated rejection have been defi ned [71] and the diagnostic categories 
for renal allograft  biopsies updated in the Banff  ’05 meeting report [72]. 
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Table 2. The Banff ‘97 working classifi cation of renal allograft pathology
Histopathological fi ndings Category
Acute rejection
Suspicious for acute rejection: mild tubulitis and 
interstitial infl ammation, no arteritis
     - t1 and at least i1
Borderline
Tubulointerstitial: signifi cant interstitial infi ltration 
and moderate tubulitis 
     - t2 and at least i2
IA
Tubulointerstitial: signifi cant interstitial infi ltration 
and severe tubulitis
     - t3 and at least i2
IB
Vascular: mild to moderate intimal arteritis 
     - v1 IIA
Vascular: severe intimal arteritis (>25% luminal 
area)
     - v2
IIB
Vascular: transmural arteritis and/or fi brinoid 
change and necrosis of medial smooth muscle cells
     - v3, lymphocytic infl ammation
III
Chronic allograft  nephropathy*
Mild interstitial fi brosis and tubular atrophy
     - ci1 and ct1 I 
Moderate interstitial fi brosis and tubular atrophy
     - ci2 and ct2 II
Severe interstitial fi brosis and tubular atrophy and 
tubular loss
     - ci3 and ct3
III
* Grading may be modifi ed by “a” no changes suggestive of chronic rejection or “b” specifi c 
changes strongly suggestive of chronic rejection present.
5.2.5 Histocompatibility
HLA compatibility aff ects transplant immunity in several ways. Humoral 
immunity against HLA antigens is one major risk factor for chronic 
rejection [73, 74]. Direct recognition of HLA antigens on the surface of 
donor APCs results in strong T-cell response. Th is type of reactivity is 
extinguished with time, whereas indirect alloreactivity can be long-lasting 
due to the continuous supply of HLA antigens by the in situ transplant. 
Th e indirect mechanism may contribute to the development of chronic 
rejection [75]. Although HLA matching is benefi cial in clinical TX, the 
enormous polymorphism of the HLA system makes it impossible to fi nd 
a HLA identical unrelated donor. As the genes encoding for the HLA 
molecules are clustered and oft en inherited as a fi xed haplotype, the 
chance to fi nd a completely HLA-identical family donor is about 25%. 
However, it is clear that most patients will be transplanted a graft  from a 
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HLA mismatched donor. To improve graft  survival and enable tapering of 
immunosuppressive treatment, it is important to minimize the degree of 
HLA incompatibility. 
Tissue typing for kidney TX includes HLA and ABO matching, serum 
screening for HLA antibodies and cross-matching with donor cells. HLA 
antigens coded by loci HLA-A, -B, and –DR are commonly considered in 
clinical matching protocols. In Finland, a maximum of three mismatches, 
with no more than two in HLA – A and – B, and no more than on in 
–DR loci is accepted. Transplants with zero ABDR mismatches have the 
best graft  survival rates [76, 77]. However, many of these transplants fail 
and many ABDR mismatched transplants have good long-term function, 
refl ecting the inadequacy of merely counting the mismatched HLA-A, -B, 
and –DR antigens. Th e immunogenity of HLA mismatches may diff er, and 
certain “acceptable” mismatches are hardly recognized by the immune 
system of the recipient, while others are highly immunogenic in patients 
with some HLA phenotypes [78, 79]. Recent studies have revealed that 
anti-HLA antibodies participate in chronic rejection process and are an 
important risk-factor for long-term graft  function [80, 81].
5.3 Immunosuppression
Prevention of acute rejection remained a major challenge for successful 
organ transplantation until the late 1970s and early 1980s when 
cyclosporine A (CsA) was introduced in clinical TX [82]. Today, the 
short- and medium-term results are impressive while the long-term graft  
survival remains a challenge, predominantly due to CAN. Currently a 
wide spectrum of diff erent immunosuppressive drug schedules aimed 
at preventing or reversing rejection are available. Th e side-eff ects (e.g. 
nephrotoxicity, hypertension, hyperlipidemia) of some immunosuppressive 
agents have been implicated in the pathogenesis of CAN. Moreover, 
current immunosuppressive agents lack specifi city, i.e. reduction in 
immune responsiveness to the allograft  is refl ected in reduced immunity to 
infection or malignant disease. In order to minimize the side eff ects of any 
single drug while maintaining adequate immunosuppression, combination 
therapy targeting at multiple steps of T-cell activation is essential (Figure 2). 
Immunosuppressive protocols consist of initial and maintenance therapies 
to prevent rejection, and short-course therapies to treat episodes of acute 
rejection. Th e maintenance immunosuppresive drugs may be categorized 
according to their mechanisms of action as 1) calcineurin inhibitors, 2) 
anti-proliferative agents, 3) glucocorticoids, and 4) TOR-inhibitors.
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Figure 2. Multiple targets for immunosuppressive agents: Stimulation of T-cell receptor 
(TCR) results in calcineurin activation, a process inhibited by cyclosporine A (CyA) and 
tacrolimus. Calcineurin dephosphorylates NFAT (nuclear factor of activated T-cells) 
enabling it to enter nucleus and bind to interleukin (IL) -2 promotor. Corticosteroids 
inhibit cytokine gene transcription in lymphocytes and antigen-presenting cells by 
several mechanisms. Costimulatory signals are necessary to optimise T-cell IL-2 gene 
transcription, prevent T-cell anergy, and inhibit T-cell apoptosis. Experimental agents 
but not current immunosuppressive agents interrupt these intracellular signals. IL-2 
receptor stimulation induces the cell to enter cell cycle and proliferate, a process that 
may be blocked by IL-2 receptor antibodies, or by sirolimus, which inhibits second 
messenger signals induced by IL-2 receptor ligation. Following progression into cell cycle, 
azathioprine and mycophenolate mofetil (MMF) interrupt DNA replication by inhibiting 
purine synthesis. (Adapted from Denton et al [54]).
5.3.1 Calcineurin inhibitors
CsA is the prime representative of agents inactivating intracellular 
calcineurin, a pivotal enzyme in T-cell receptor signaling. CsA binds 
to a cytoplasmic receptor, cyclophilin, and the complex inhibits the 
calcineurin-dependent IL-2 gene transcription during the early phase of 
T-cell activation, thereby inhibiting T-cell IL-2 production [83]. In the 
absence of IL-2, a powerful T-cell growth factor, the generation of cytotoxic 
T-cells is attenuated. Th e main target of CsA action is the Th -lymphocytes. 
Tacrolimus (Tac) has been developed as an alternative agent to CsA, and 
it has gained ground in clinical TX during the past few years [84]. Tac 
binds to a cytoplasmic receptor, FK-binding protein, and similarly to CsA, 
inactivates calcineurin. However, Tac is a more potent immunosuppressant 
than CsA, presumably due to a greater affi  nity to calcineurin [85].
Several important adverse eff ects are related to the therapeutic use of 
calcineurin inhibitors. Known adverse reactions are similar for both CsA 
and Tac, although the exact balance diff ers between the two [54, 86]. Th ey 
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are roughly equivalent in nephrotoxicity, which may occur acutely aft er 
TX, or chronically over time. Acute nephrotoxic eff ects occur secondary 
to intrarenal vasoconstriction and may exacerbate ATN. Th e acute eff ects 
are reversible and respond to lowering of the dose. Th e permanent chronic 
nephrotoxic eff ects are propably a sequela of persistent vasoconstriction 
and ischemia as well as induction of fi brinogenic growth factors [87, 88]. 
Th ese eff ects are characterized histologically by obliterative vasculopathy 
and interstitial fi brosis. Hypertension and hyperlipidemia are frequent 
fi ndings in CsA treated patients, whereas diabetes mellitus and neurotoxic 
reactions are more common in patients receiving Tac. Hirsutism and 
gingival hyperplasia are usually related to CsA treatment [89]. 
5.3.1.1 Cyclosporine A pharmacokinetics
CsA is a drug of narrow therapeutic window with broad inter- and intra-
individual pharmacokinetic variability [90]. Moreover, pharmacokinetics 
of CsA in children diff er from that in adults, for example CsA metabolism 
is faster in young children [91]. CsA is metabolized via the 3A4 isoentzyme 
of cytochrome P450 (CYP) in the liver, and concomitant therapy with 
inducers or inhibitors of CYP3A4 may result in decreased or elevated 
blood CsA concentration [92]. Th e conventional formulation of CsA 
(Sandimmun®) exhibits considerable variability in bioavailability, whereas 
the more recent microemulsion formulation (Neoral®) shows more 
uniform intestinal absorption and greater bioavailability [93]. Albeit the 
microemulsion formulation has replaced the conventional formulation 
in clinical use, there remain considerable diff erences in bioavailability 
and clearance of CsA, especially in young children [94, 95]. Since serious 
clinical consequences may occur as a result of under- or overdosing of 
CsA, individualized dosing and therapeutic drug monitoring is necessary 
[96, 97]. 
Area under the concentration – time curve (AUC) reveals systemic 
exposure of a drug, but it is an inconvenient method for routine monitoring 
due to multiple sample collection requirements. CsA monitoring has been 
traditionally based on pre-dose (trough) blood concentrations, but poor 
correlation between blood CsA trough level (C0) and AUC [98, 99] has 
undermined the appropriateness of C0 monitoring in clinical practice. 
Pharmacokinetic studies have shown that the greatest intra- and inter-
patient variability in CsA absorption occurs during the fi rst 4 hours aft er 
dosing, and this absorption phase is crucial in determining the clinical 
outcome [99]. Moreover, the greatest calcineurin inhibition and the 
maximum inhibition of IL-2 production by CsA appear to occur during 
the fi rst 1–2 hours aft er dosing [100]. Several limited sampling strategies 
have been proposed to predict the full-scale AUC of CsA, although none of 
them has gained popularity in clinical practice [101]. Instead, the two-hour 
post-dose concentration (C2) has become widely accepted as a single-point 
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estimate of CsA exposure. C2 correlates well with AUC0-4 hours [102], 
and adjustment of CsA dosing based on C2 monitoring appears clinically 
feasible [103]. In adults, adequate C2 levels are associated with reduced risk 
of AR [104–106], as well as reduced toxicity [107], and a target level has been 
defi ned at 1500 μg/L in the immediate post-TX period, tapering down to 
800 μg/L aft er twelve months [103, 108]. C2 has proved a reliable surrogate 
marker for CsA AUC in children as well [109–114]. Similar concentrations 
to adults have been reported to relate to freedom from AR [94, 113], 
although conclusive target levels for C2 are yet to be defi ned in children 
[115, 116]. Furthermore, C2 monitoring may have some disadvantages. Th e 
steep slope of the concentration – time curve during the fi rst four hours 
post-dose necessitates punctual sample collection in C2 monitoring with 
no more than 15 minutes error tolerance [108], which requires education 
of the patients and the medical staff . Secondly, C2 monitoring alone may 
not be suffi  cient to identify fast and slow absorbers and these patients may 
thus be predisposed to AR or toxicity. Th e individual variability in CsA 
AUC is schematically illustrated in Figure 3.
Th e individually variable pharmacokinetic parameters of CsA can be 
estimated by performing a pre-transplantation pharmacokinetic study for 
each patient [91]. Th e pharmacokinetic profi le obtained in such a study 
may help to identify the patients who need very high or low doses of CsA, 
e.g. genetically fast or slow metabolizers, or poor absorbers. Also, young 
children may require two to three fold larger doses than school-aged or 
older children. Th e pharmacokinetic profi le may be utilized to calculate 
individual dosing recommendations, aiming at a pre-defi ned target blood 
concentration. However, the profi le is based on a single dose in the pre-
transplantation state, and the calculated recommendations cannot be more 
than indicative of the individual doses needed aft er TX. 
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Figure 3. Examples of three potential CsA pharmacokinetic profi les aft er oral 
administration, illustrating very diff erent C2, C0, and time of maximum concentration. 
Profi le 2 is the most common, but other types of pharmacokinetic profi les are also 
encountered.  
5.3.1.2 Tacrolimus
Tac shares with CsA the drawback of having a narrow therapeutic 
window. It also shows considerable intra- and inter-patient variability 
in its pharmacokinetics. As a substrate for the CYP3A enzymes and 
P-glycoprotein, tacrolimus metabolism may be infl uenced by concomitant 
use of inducers or inhibitors of the same mechanisms [117]. Several factors 
have been reported to infl uence the pharmacokinetics of tacrolimus, e.g. 
organ transplanted, hepatic function, patient age, ethnicity, time aft er TX, 
and corticosteroid dosage [118]. As a result, individualized dosing and 
drug level monitoring is required. Traditionally, Tac monitoring has been 
based on the trough level. In adults, the trough level has been shown to 
correlate with AUC as well as clinical outcome, although recent studies 
have questioned the reliance on trough monitoring [118].
Tac has become a potent alternative to CsA in pediatric recipients of liver 
or kidney transplants over the past decade [30, 119, 120]. Pharmacokinetic 
characteristics of Tac observed in adults may not be fully applicable to 
pediatric patients, and dosing requirements may thus be diff erent. Young 
children clearly require higher doses than older children and adolescents 
[121–124]. In addition, large interindividual variability and poor correlation 
























Antiproliferative agents prevent the expansion of alloactivated T- and B-cell 
clones. Th e prototype of antiproliferative agents is the purine analogue, 
azathioprine, which has been used as an immunosuppressive since 1960s’. 
AZA is converted in the liver into the active metabolite 6-mercaptopurine, 
and it inhibits DNA synthesis. Th e principal adverse eff ect is bone-marrow 
suppression, but AZA has been also implicated in liver damage and in the 
development of pancreatitis. However, AZA is usually well tolerated at the 
low doses (1–2 mg/kg/d) used in combined therapy. AZA is not eff ective 
in the treatment of an ongoing rejection. Th e effi  cacy of the drug correlates 
with the tissue concentration and monitoring of blood or serum levels is 
thus not useful for AZA. 
Mycophenolic acid, which fi rst became available as a prodrug 
formulation, mycophenolate mofetil (MMF), and later as an enteric-coated 
mycophenolate sodium formulation, is selective inhibitor of the de novo 
pathway of purine biosynthesis, thereby providing more specifi c and potent 
inhibition of T- and B-cell proliferation [125]. When used for maintenance 
immunosuppression in combination with calcineurin inhibitors, MMF 
appears more eff ective than AZA in preventing acute rejections [126]. 
Utilization of MMF in pediatric renal TX patients has increased markedly 
during the past decade [30]. Th e main side eff ects relating to MMF use 
are gastrointestinal disorders and to a lesser extent, myelotoxicity. In 
children, diarrhea, leukopenia, and anemia are the most common causes 
leading to dose reduction or interruption of MMF therapy [127]. Th ere is 
considerable variability in the pharmacokinetics of MMF both within and 
between transplant patients [128]. In children, dosing is generally based 
on the body surface area (normally 1200 mg/m2/d for MMF) and trough 
concentration monitoring is recommended, although the optimal drug 
monitoring strategy for MMF in children is unclear [127].
5.3.3 Glucocorticoids
Glucocorticoids (GCs) are non-specifi c anti-infl ammatory agents. 
According to the classical model of GC action, the eff ects are mediated 
through glucocorticoid receptor (GR), a cytosolic ligand-activated 
transcription factor, belonging to the nuclear receptor superfamily [129]. 
Th e receptor-steroid complex translocates to the nucleus where it binds 
to steroid response elements in the promoters of a large number of genes, 
and either activates or represses gene expression [130]. GCs inhibit the 
production of several cytokines and growth factors by APCs, T-cells and 
macrophages, thereby disrupting antigen presentation, T-cell activation 
and macrophage-mediated tissue injury [131, 132]. Th ey also inhibit 
vasodilatation and decrease vascular permeability. Th e actions of GCs at 
the cellular level are immensely complex, but in sum, the eff ects are highly 
immunosuppresive. GCs have numerous well recognized adverse eff ects 
including infection, adrenal suppression, hypertension, hyperlipidemia, 
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growth suppression, glucose intolerance and diabetes mellitus, osteoporosis, 
cataracts, acne, cushingoid appearance, weight gain and changes in mood 
or behavior [133]. 
High-dose course of GC treatment is used perioperatively in 
organ TX, and is the fi rst-line therapy for AR [134]. In maintenance 
immunosuppression, GCs are commonly used in combination with 
antiproliferative agents and/or calcineurin inhibitors. According to 
the NAPRTCS database over 90% of children receive GC therapy aft er 
renal TX [30]. Prednisone, prednisolone and methylprednisolone are 
the most frequently used preparations in clinical transplantation. Th e 
anti-infl ammatory potency of prednisone and MP is estimated to be 4 
and 5 times greater than that of endogenous cortisol, respectively, with 
very little mineralocorticoid activity [133]. Both prednisone and MP 
have clinically signifi cant growth-retarding eff ect, which is manifested 
in sub-optimal growth aft er TX [48]. Alternate day dosing of prednisone 
and MP may alleviate the adverse eff ects, particularly suppression of the 
hypothalamic-pituitary-adrenal axis [133]. Because of the far reaching 
adverse eff ects, steroid-free protocols in pediatric TX have been 
investigated. Although promising short-term results have been reported 
the long-term results remain unclear [135].
In immunosuppression protocols, dosing of GCs is oft en standardized, 
or based on weight, or less frequently on body surface area. GC 
pharmacokinetics, however, exhibit a broad range of interindividual 
variability, which may contribute to diff erences in immunosuppressive 
effi  cacy and occurrence of adverse eff ects [136, 137]. In pediatric TX 
patients MP exposure, instead of dose, has been shown to correlate with 
growth retardation and adrenal suppression [138]. Factors infl uencing 
GC pharmacokinetics include age, gender, obesity, and drug interactions. 
Considering the extensive use of this relatively old class of drugs, 
remarkably few studies on the pharmacokinetics of GCs in children have 
been conducted. 
5.3.4 Target of rapamycin (TOR) -inhibitors
Rapamycin (sirolimus) was fi rst investigated for antifungal properties, but 
was later (in 1988) discovered to possess immunosuppressive properties. 
Rapamycin inhibits TOR, a cytosolic enzyme that regulates diff erentiation 
and proliferation of lymphocytes. TOR-inhibitors may be important in long-
term immunosuppression as they stimulate T-cell apoptosis and inhibit 
mesenchymal proliferation. TOR-inhibitors may be used in combination 
with other immunosuppressive drugs as the mechanism of action is 
diff erent. Th e pharmacokinetics of rapamycin in children diff ers from 
that in adults [139], and blood level monitoring appears useful [140]. Th e 
major adverse eff ects of rapamycin are hyperlipidemia, thrombocytopenia 
and leucopenia [141]. Everolimus is a derivative of rapamycin and works 
similarly as an inhibitor of TOR.
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5.3.5 Induction immunosuppression
Th e risk of graft  rejection is highest in the immediate post-TX period. 
Immunosuppression is, therefore, initiated with higher doses of 
maintenance immunosuppresives, oft en accompanied with induction 
antibody therapy. Induction antibody therapy may involve a short course 
of potent anti-T-cell antibody preparation (anti-CD3 antibodies, anti-
thymocyte and anti-lymphocyte globulins). In the early years, a polyclonal 
antibody prepared from horse serum was used. A monoclonal antibody, 
and standardized polyclonal antibodies were subsequently employed. In 
the recent years the use of antibodies against more specifi c targets, anti-IL-2 
receptor antagonists (daclizumab, basiliximab) in particular, has increased 
[84]. While patients at increased risk for AR may benefi t from antibody 
therapy, it may not be without the risk of serious adverse eff ects [142–144]. 
IL-2 receptor antibody induction therapy, however, appears eff ective and 
well-tolerated [145], also in children aft er renal TX [146]. According to 
the NAPRTCS database, 48% of pediatric patients received basiliximab or 
daclizumab induction therapy at renal TX [30]. Th ese agents are generally 
administered for a limited period aft er the operation, but eff ective IL-2 
receptor blockade is achieved for several weeks, thereby covering the 
critical period  when AR is most common [146, 147].
5.3.6 Novel immunosuppressants
Th e introduction of monoclonal IL2-receptor antibodies in the 1990s 
marked the emergence of novel biologic agents in transplantation. A new 
generation of biologic agents is also being developed for maintenance 
immunosuppression with the purpose of replacing calcineurin inhibitors 
and GCs. While the costimulatory pathway in T-cell activation is an 
important therapeutic area, other potential targets include interleukins 
and adhesion molecules. Alemtuzumab is a potential T-cell depleting 
monoclonal antibody, targeting the CD25 antibody expressed on 
lymphocytes and monocytes. It has been used in induction therapy and 
maintenance immunosuppression aft er renal TX, but increase in rejection, 
changes in T-cell subpopulation and risk of malignancy and infections are 
disturbing drawbacks. Another potential target for inhibition is the IL-15 
pathway. IL-15 is a cytokine promoting antiapoptosis signals, and elevated 
levels of IL-15 expression have been found in rejecting graft s. Interaction of 
CD28 and cytotoxic lymphocyte antigen-4 (CTLA-4) with their receptors 
CD80 and CD86 costimulates T-cell activation. Th eir blockade is the focus 
of new promising therapies [148]. Several small molecules other than 
antibodies with immunomodulatory and immunosuppressive properties 
have also been developed and investigated [149].  
33
5.4 Rejection and pathology of the kidney allograft
Despite the improvements in the management of immunosuppressive 
regimens, rejection remains a serious concern as it may lead to graft  loss 
and patient death. AR is an important risk factor for CAN leading to 
deteriorating graft  function [150–152]. In recent years there has been a 
continuing trend of declining frequency of AR in pediatric TX patients, 
which may translate into less CAN [30, 153]. Th e 12-month probability 
of fi rst rejection in LRD and CAD transplantations has decreased from 
54% and 69% in 1987–90 to 13% and 16% in 2003–05, respectively [154]. 
However, the use of potent immunosuppressive therapy may increase the 
risk of post-TX infections and lymphoproliferative disorders [30, 155–157]. 
Th e management of pediatric TX patients requires continuous balancing 
between the risks of over-immunosuppression and the consequences of 
graft  damage due to rejection. In the future, a better understanding of 
rejection mechanisms may hopefully allow for better adaptation of the 
immunosuppressive regimen to each patient.
5.4.1 Diagnosis of acute rejection
Th e classic signs of acute renal allograft  rejection include tenderness 
and swelling of the graft , decreased urine outfl ow and fever. In the CsA 
era, the clinical signs are seldom seen and AR is oft en suspected on a 
rising serum creatinine concentration. Other causes of graft  dysfunction 
cannot be distinguished with certainty from rejection without histologic 
examination. A renal core biopsy and grading of the fi ndings according to 
the Banff  criteria [70, 72] is the gold standard in diagnosing rejection. In 
this study, the Banff  ’97 classifi cation has been used. 
As a less traumatic method, that may be repeated frequently without 
general anesthesia in children, fi ne-needle aspiration biopsy (FNAB) allows 
diagnosis and follow-up of acute cellular rejection in pediatric patients [43, 
158]. To describe the intensity of infl ammation, a total corrected increment 
(TCI) [159] and the number of lymphoblasts per preparate (blast count) 
are recorded, and samples with a TCI value <3 and the blast count <3 are 
regarded normal. FNAB samples with a TCI score of 3–5 and the blast count 
up to fi ve indicate mild immunoactivation, whereas a TCI score >5 and 
the blast count >5 yield the diagnosis of a cytological rejection [160–162]. 
A core needle biopsy for light microscopy and immunohistochemistry is 
necessary when vascular or steroid-resistant rejection is suspected, or a 
histological evaluation of the graft  is needed. FNAB is suitable for routine 
screening of AR during the post-TX hospitalization, and it allows early 
detection of immunoactivation before major clinical signs appear, as well 
as diff erentiation of other causes for the clinical signs of rejection [43]. 
However, reliable FNAB diagnostics requires expertise in interpretation of 
the cytological fi ndings.
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5.4.2 Treatment of acute rejection
Th e most common treatment of AR in pediatric kidney allograft  recipients 
is a course of intravenous GC, usually MP with doses upto 30 mg/kg/d for 
3–5 days [163]. Th e therapy is oft en followed by increased doses of oral GC 
for several weeks [134]. Most acute rejection episodes are reversed with 
GC therapy, but some remain steroid-resistant and require other therapies, 
such as anti-thymocyte-globulin or anti-CD3-antibodies [164]. In 
patients with severe humoral rejection, non-standard treatment, including 
plasmaphresis, cyclophosphamide and immunoglobulin administration 
may be attempted [165]. 
Th e reasons why an AR episode occurred should be carefully 
analyzed. Occurrence of AR may be indicative of too weak baseline 
immunosuppression. Th erefore, it is reasonable to consider changes in the 
baseline regimen aft er the AR has been reversed. In case of sub-therapeutic 
drug concentrations, adjustment of dosing and close drug concentration 
monitoring is warranted. A temporary increase in GC dosing may also 
be appropriate. On the other hand, if a rejection occurs despite adequate 
immunosuppression, conversion to other drugs might be indicated, 
e.g. CsA can be replaced with Tac [166], and/or AZA with MMF. Non-
compliance is a common situation in patients with late AR (> 1 year aft er 
TX), most noticeably in the adolescent age-group [167–169].
5.4.3 Subclinical rejection
While the current immunosuppresive regimens oft en suppress the clinical 
signs of rejection, allograft  immunoactivation cannot be excluded even in 
cases with no graft  dysfunction. A subclinical form of allograft  infl ammation 
has been characterized, with the presence of histologic fi ndings meeting the 
criteria for rejection in the absence of clinical manifestations or laboratory 
perturbations [170]. With protocol biopsies, the incidence of subclinical 
rejection has been reported at 30%–45% in adult renal TX patients 
[170–172]. Diagnosis and subsequent treatment of subclinical rejection 
has been shown to result in improved outcome in terms of lower serum 
creatinine and less chronic rejection two years aft er TX [173]. However, 
with the use of potent early immunosuppressive therapy (Tac, MMF, 
prednisone, induction therapy) the incidence of subclinical rejection 3 
months aft er TX has been reported as low as 2.6% [174]. Furthermore, 
in some situations the natural course of subclinical infl ammation may be 
benign [172, 175], although it has also been reported to be a risk factor for 
late graft  damage and loss [176, 177]. In a recent study on Finnish pediatric 
renal TX patients, early treatment of AR (both clinical and subclinical) was 
found to be related to good long-term graft  function [178]. 
Th e risk that AR will go unrecognized may be even greater in children 
than adults. Th e transplantation of an adult-sized kidney into a small child 
creates a disproportionately large renal mass related to body mass. It is 
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possible that this large renal mass conceals the clinical manifestations of 
AR, including rise in serum creatinine [179]. Similarly to adults, cellular 
rejection is detected in up to 50% of pediatric patients in protocol biopsies 
during twelve months aft er TX, and is associated with the progression of 
chronic allograft  nephropathy [180, 181]. Furthermore, serum creatinine 
or calculated clearance may not accurately refl ect the histologic severity of 
allograft  nephropathy in children [180]. 
Currently, reliable non-invasive surrogate markers of rejection do not 
exist, and protocol biopsy is the method to allow early diagnosis of subclinical 
rejection [182]. Th e procedure of renal core biopsy is associated with a risk 
of complications, e.g. serious hemorrhage [172]. Th e risks must be balanced 
with the potential diagnostic benefi ts, although the actual frequency of 
signifi cant complications is extremely low in pediatric patients [183].
5.4.4 Chronic allograft nephropathy
Th e past decades have witnessed dramatic improvements in reducing AR 
and early allograft  failures aft er kidney TX, but whether there has been 
a substantial improvement in the rate of late allograft  failure remains 
controversial [184, 185]. Chronic rejection, or CAN, is the most common 
cause for graft  loss in pediatric renal TX recipients, accounting for one third 
of the reported graft  losses [154]. CAN is used to denote the pathology of 
fi brosis and atrophy in a progressively failing renal allograft , and it remains 
a main clinical challenge. Th is time-dependent, variable, progressive 
allograft  damage is mediated by a combination of alloimmune, ischemic and 
infl ammatory stimuli [186]. Calcineurin inhibitors and steroids have been 
implicated in the increased production of TGF-β1, a cytokine initiating 
proinfl ammatory fi broproliferative cascades, which may have an important 
role in the development of CAN and nephrotoxicity [187]. Chronic CNI 
toxicity is characterized histologically by patchy tubular atrophy with 
striped interstitial fi brosis, and nodular hyalinosis of arteriole walls may 
be seen. Although not intrinsic to CNI toxicity, glomerulosclerosis may 
arise as a complication to long-standing toxicity. Methods advocated for 
distinguishing CNI toxicity from other chronic changes include analysis 
of tissue collagen type, assessment of tissue mRNA for laminin β2 and 
TGF-β. Th e histological features associated with CAN are schematically 
illustrated in Figure 4.
5.4.5 Viral infections
Immunosuppression is a major risk factor for infection following TX. All 
current regimens impair the host’s ability to fi ght infection. Viral pathogens, 
especially those of herpesvirus family, are a major source of morbidity and 
mortality. Th e most common viral infection is by cytomegalovirus (CMV), 
and it can be caused by primary infection, reactivation of latent infection or 





from an organ donor, is associated with the greatest morbidity whereas 
reactivation tends to result in milder disease. Th e use of antiviral agents 
(e.g. ganciclovir) as prophylaxis and treatment has greatly decreased the 
rate and severity of  CMV disease [188]. Epstein-Barr virus (EBV) infection 
is associated with post-transplant lymphoproliferative disorders (PTLD), 
especially in pediatric patients. Symptomatic EBV infection and PTLD in 
particular, is more common aft er primary infection (usually from an organ 
donor). Antiviral agents and intravenous immunoglobulins have been used 
as preventive strategies against PTLD [188]. Many micro-organisms have 
been described in transplanted kidneys but currently the most common 
and clinically important is polyoma virus, especially the BK strain (BKV). 
Th e major clinical manifestation of BKV infection is tubulointerstitial 
nephritis. Early identifi cation (e.g. screening of urine or blood for the 
presence of BKV DNA) and due reduction of immunosuppression is 
recommended to prevent progression of BKV nephropathy to irreversible 
interstitial fi brosis and tubular atrophy [188].
Figure 4. Schematic illustration of biopsy features of a renal allograft  showing 
histopathological features characteristic of CAN. Italicized words indicate potential 
precipitating factors for CAN associated with the areas they specifi cally target (Adapted 
from Alexander et al [189]).
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Th e aggregate injury from immunologic and non-immunologic causes 
during the fi rst six months aft er TX may be crucial in setting the fate of the 
kidney allograft  [190, 191]. Surveillance biopsies obtained six months or 
later aft er TX may be very important in diagnosing CAN and predicting 
outcome. Due to the multiple pathophysiological causes of CAN (Figure 5), 
no single therapy will prevent or abrogate the injury. Ideally, individually 
tailored therapy should be initiated prior to, or during periods of active 
injury to prevent permanent nephron destruction. Recently it has become 
evident that the various causes leading to scarring and graft  dysfunction 
should be categorized into more detail, particularly antibody-mediated 
chronic rejection should be classifi ed as its own entity [72], allowing more 
specifi c therapies.
Figure 5. Pathophysiology of allograft  damage. Th e interaction between donor 
quality, transplantation events and subsequent immune and nonimmune insults 
upon histological compartments leading to allograft  damage and transplant failure. 
AH, arteriolar hyalinosis; AR, acute rejection; ATN, acute tubular necrosis; CNI, 
calcineurin inhibitors; DGF, delayed graft  function; FIH, fi brointimal hyperplasia; 
HLA, human leukocyte antigen; PTH hyperparathyroidism, PRA, panel reactive 
antibodies; ROS, reactive oxygen species; SCR, subclinical rejection; TCR, true chronic 
rejection. (Adapted from Nankivell and Chapman [186]).
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6. AIMS OF THE STUDY
Pediatric transplant recipients are faced with life-long, undisrupted 
use of immunosuppresive medication. Despite the rapid development 
of new immunosuppressive agents, the drugs currently in use infl uence 
the immune system in a non-specifi c manner, thus bearing the risks of 
signifi cant adverse eff ects. In pediatric patients, the consequences of 
over- or under-immunosuppresion cast a shadow over the prospects 
of normal development and growth, and quality of life for decades. 
Many immunosuppresive protocols have been adopted from adults, 
although there are signifi cant diff erences in the pharmacodynamics and 
pharmacokinetics in children. Moreover, it has become evident that an 
individualized approach in the care of transplant patients is a requisite for 
optimal outcome. 
Th e aims of the study were to analyze whether individually tailored 
immunosuppression helps to reduce rejection and improve graft  function, 
and to avoid steroid related adverse eff ects in children aft er kidney 
transplantation, with special emphasis on: 
– Individualized cyclosporine A dosing based on pre-TX pharmacokinetic 
profi les.
– Diagnosis and treatment of subclinical rejection, based on early protocol 
biopsy and a frequent monitoring of graft  function.
– Monitoring of cyclosporine A blood concentrations two hours aft er 
dose, in addition to pre-dose levels.
– Methylprednisolone exposure and its relation to the steroid-related 
weight-gain and growth retardation. 
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7. PATIENTS AND METHODS
7.1 Ethical considerations
Th e study design was approved by the Ethics Committee for pediatrics, 
adolescent medicine and psychiatry of the Hospital for Children and 
Adolescents, University of Helsinki. Informed consent was obtained from 
patients and/or parents prior to their inclusion in the study, when eligible. 
7.2 Patients
All pediatric renal transplant patients were eligible for the study. A total of 
178 children had received a kidney transplant by April 2006. Overlapping 
subgroups of these patients were included in studies I to IV. In all studies the 
most common single cause for renal TX was NPHS1, and the proportion 
of young (<2 years) recipients was approximately 30%. Th e average waiting 
time has slightly increased over the years, as has the number of CAD TX as 
well. Patient demographic data in the studies is presented in Table 3. 
Study I (individual CsA dosing) included 65 patients, who had received 
their fi rst renal transplants between 1988 and 1998. All patients had 
completed a pre-TX CsA pharmacokinetic study, and received CsA, MP 
and AZA aft er TX.
Study II (subclinical rejection) included 59 patients. Twenty-four 
patients, who received kidney transplants between 1999 and 2001, and were 
treated according to a revised protocol, were compared with 35 historical 
controls, who had received transplants between 1995 and 1999. Th e control 
group received CsA, MP and AZA aft er TX. Th e revised protocol included 
induction therapy with basiliximab, triple immunosuppression with 
CsA, MP and AZA, a renal core biopsy at 3 months, and adjustment of 
immunosuppression based on histology and graft  function. Two patients 
in the revised protocol group died one and four months aft er TX. 
Study III (C2 monitoring) included 47 patients, who received renal 
transplants between 2001 and 2006. Th e patients received induction 
therapy with basiliximab and triple immunosuppression with CsA, MP 
and AZA aft er TX. In addition to the conventional trough level, two-hour 
post-dose concentrations were utilized in CsA monitoring. 
40
Study IV (MP exposure) included sixteen stable renal TX patients, 
who were scheduled for a regular follow-up visit to the hospital between 
September 2003 and July 2004. In compliance with the inclusion criteria 
for the study, all patients were over fi ve years of age (12.9±2.8 years), 
at least six months time had elapsed aft er renal TX (7.0±3.1 years), the 
patients received alternate day doses of MP as a part of their maintenance 
immunosuppression, and they had normal adrenal function.
Table 3. Demographic data of patients included in studies I to IV 
Study I Study II Study III Study IV
Number of patients (male / female) 65 (48/17) 59 (39/20) 47 (28/19) 16 (12/4)
Age at TX (mean±SD, years) 









Diagnosis NPHS1/other 30/35 17/42 14/30 7/9
Time on dialysis (mean±SD, years) 0.8±0.7 1.3±1.0 1.4±1.0 1.0±0.6
Donor source LRD / CAD 22/43 15/44 6/41 6/10
AB/DR mismatch (average) n/a 1.7/0.6 1.6/0.7 1.6/0.6
Re-transplantations 0 2 1 1
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7.3 METHODS
Children with a weight over 9 kg and without a major neurodevelopmental 
illness were accepted for transplantation. Patients with NPHS1 were 
nephrectomized bilaterally in order to normalize protein and coagulation 
status, nutrition, and sensitivity to infections prior to TX [192]. ABO 
compatibility and a negative T-cell crossmatch were prerequisites for TX. 
A maximum of three mismatches, with no more than two in HLA-A and 
-B and no more than one in –DR loci, were accepted. All LRD graft s were 
from a parent. Th e transplanted graft s were placed extraperitoneally in the 
right iliac fossa.
 7.3.1 Immunosuppression protocol
Baseline protocol. All patients received triple immunosuppression 
consisting of MP, AZA and CsA. MP was started intra-operatively 100 mg 
i.v. divided in three doses, and continued post-operatively 1 mg/kg/day until 
3 weeks when the dose was tapered down to 0.25 mg/kg/day. Th e dose was 
further reduced to 0.37 mg/kg every other day aft er three months. AZA was 
given intra-operatively 1.4 mg/kg i.v. divided in two doses, and continued 
post-operatively 2 mg/kg, which was reduced to 1 mg/kg/day aft er two 
weeks, and increased to 1.4 mg/kg/day aft er three months when the steroid 
was reduced. CsA was initiated pre-operatively with pharmacokinetically 
determined individual doses, aiming at a trough concentration 300 μg/L. 
Six months aft er TX the target concentration was reduced to 100 μg/L. CsA 
was administered in three doses in children younger than eight years, and 
in two doses in older children.
Revised protocol. Th e immunosuppression protocol was slightly revised 
in September 1999, when basiliximab induction therapy was introduced. 
Basiliximab was given in two doses, a bolus of 10 mg in children weighing 
<30 kg, and 20 mg in those weighing >30 kg, intra-operatively and on 4th 
day aft er TX. Triple immunosuppression was initiated according to the 
baseline protocol. Aft er three months, immunosuppression was adjusted 
individually based on graft  histology and function. MP dose was reduced 
(but not discontinued) in patients with well functioning graft s and normal 
histology. In cases of immunoactivation, MP was continued with daily 
doses. In some patients with immunoactivation (or drug related adverse 
eff ects in few patients) CsA was replaced with tacrolimus, and/or AZA 
with MMF.
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7.3.2 Cyclosporine formulation, blood concentration and 
pretransplantation pharmacokinetic study
Th e conventional oil-based formulation of CsA (Sandimmun®) was 
used in standard immunosuppression until June 1995. Aft er that oral 
CsA was administered as the microemulsion formulation (Sandimmun 
Neoral®). For historical reasons, two diff erent analytical methods were 
used for determination of B-CsA. During the post-TX hospitalization, 
the daily B-CsA was analyzed using the FPIA technique (fl uorescence 
polarization immunoassay, TDX, Abbott), and the results were available 
on the same day. In the pre-TX pharmacokinetic study, and at outpatient 
visits aft er TX, B-CsA was determined by the RIA method (specifi c 
monoclonal radioimmunnoassay, Cyclo-Trac SP Whole Blood, DiaSorin), 
and the results were available the next day. Th e hospital laboratory has 
investigated the diff erences in B-CsA levels in both adult and pediatric 
patients and reported 13–28% higher concentrations with the FPIA 
method. In pediatric kidney transplant recipients, a conversion factor 
1.16 was suggested [193], and this has been used in the analyses to make 
the concentrations comparable. Th erapeutic drug monitoring of CsA was 
based on trough (pre-dose) concentration solely until 2001 when two-
hour post-dose concentration was included in routine monitoring. C2 
was determined at 1–5 day intervals aft er the patient had been switched 
to oral administration of CsA, usually aft er the fi rst 2–3 days. Even aft er 
introduction of C2 monitoring, the trough level remained as the primary 
monitoring parameter. C0 was targeted at 250–350 μg/L in the immediate 
post-TX period. Aft er 6 months the target level for C0 was lowered to 100 
μg/L. C2 concentrations 1500 -1800 μg/L early aft er TX, and 800–1000 
μg/L aft er six months were considered appropriate, although these were 
not defi ned targets. 
In the pre-TX pharmacokinetic study [194], CsA was given twice: as 
an intravenous 4-hour infusion of 3 mg/kg, and as a single oral dose of 
10 mg/kg with a drug-free interval of at least 24 hours between the two 
administrations. Th e B-CsA was determined from samples taken before 
and at 0, 1, 2, 3, 4, 6, 9, 12, 16 and 24 hours aft er the oral dose, and before, 
in the middle, and at the end of the i.v. infusion, and 0.5, 1, 2, 3, 6, 9, 12, 16 
and 24 hours aft er the i.v. infusion. Th e individual CsA dose to give target 
trough concentration on repetitive dosing was estimated as: 
Dosei.v. = Dosei.v. used x (              ) / fss,
where fss = AUC0-t / AUC0-∞ (fraction of the steady state concentration 
reached at time t), Ct target = target through concentration (300 μg/L), 
Ct observed = observed concentration, Dosei.v. used = the actual i.v. 
dose administered in the pre-TX study. Th e predicted oral doses were 




individual bioavailability F as: Doseoral = Dosei.v. / F. AUC was calculated 
using the trapezoidal method AUC0-t =Σ [(Cn+Cn+1)*(ti – ti+1)]/2, and 
AUC0-∞ = AUC0-t + Ct/ke (ke = coeffi  cient of elimination). 
Th ree daily doses, instead of two, were recommended for individuals 
with fast elimination (e.g. children <8 years of age, enzyme-inducing co-
medication). Th e trough level should equal in twice daily (BID) and three 
times daily (TID) dosing schemes but roughly 30% lower C2 should suffi  ce 
in TID, if a uniform daily AUC exposure is the aim for both dosing schemes 
[195]. On the other hand, if suffi  cient peak concentration is the aim [100], 
similar C2 target concentrations may be applied in both schemes. Dose-
interval AUC was approximated by two-point (C0 and C2) estimation in BID 
and TID patients using equations AUCBID = (9.50xC0)+(2.06xC2)+940.71, 
and AUCTID = (10.80xC0)+(1.00xC2)+715.74, respectively. In a previous 
study, these regression equations explained 77% and 82% of the AUC 
variation in Finnish pediatric renal TX patients on maintenance BID and 
TID dosing, respectively [195]. In this study, the diurnal AUC was estimated 
as AUCBID*2 and AUCTID*3 in BID and TID patients, respectively.
7.3.3 Acute rejection
Fine-needle aspiration biopsy was taken routinely on the 5th day aft er 
TX, and twice a week until the patient was discharged from the hospital. 
FNAB was also taken if a rejection was suspected on clinical grounds, i.e. 
fever, rise in serum creatinine and/or C-reactive protein concentration, 
tenderness of the graft , decreased urine output. In FNAB, a TCI higher 
than 5, and blast-cell count of at least 5 indicated AR [196] with or without 
fever and rise in serum creatinine concentration. In this study, AR was 
defi ned as an episode treated with MP (3 mg/kg/day) for fi ve days or until 
the blast cell reaction subsided. If no response was seen aft er 5 days, a renal 
core biopsy was performed, and polyclonal antithymocyte globulin or anti-
T-cell antibody was used if AR was still present. 
Subclinical rejection was defi ned as histologic changes of the graft 
fulfi lling the Banff  ‘97 criteria of AR, grade IA or more, in the absence 
of clinical signs or laboratory perturbations. If subclinical rejection was 
detected in a biopsy, the patient received the standard treatment of AR, 
and the maintenance immunosuppression was continued with daily 
dosing of GCs. A follow-up biopsy was performed 1 month later. If the 
rejection had subsided GC was reduced to every other day dosing. In 
cases of severe rejection, unsatisfactory responsiveness to treatment, or 
declining graft  function, GCs were continued with daily doses, CsA was 
replaced with tacrolimus and/or AZA with MMF. In case of borderline 
changes only, the maintenance immunosuppression was continued usually 
with daily administration of GCs. Borderline changes combined with 
declining graft  function usually indicated modifi cation of maintenance 
immunosuppression, and a follow-up biopsy within the next three 
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months. All modifi cations of maintenance immunosuppression were 
made individually based on graft  histology, graft  function, responsiveness 
to treatment and history of rejections.     
7.3.4 Renal function
Serum creatinine concentration was monitored daily during post-
operative hospitalization and at every control visit to the hospital aft er TX. 
Glomerular fi ltration rate (GFR) was measured by 51Cr-EDTA clearance, 
corrected for a standard body surface area of 1.73m2. GFR was routinely 
investigated before the patient was discharged from the hospital, and 
at 6 and 18 months aft er TX. From September 1999 onwards, GFR was 
investigated also at 3 and 12 months aft er TX.
7.3.5 Renal histopathology
Renal histology was routinely investigated 18 months aft er TX in all patients. 
From September 1999 onwards, histology was routinely investigated also 
at 3 months aft er TX. Additional biopsies were performed on clinical 
indications at any time. Percutaneous needle biopsies of the renal core were 
performed using an automated punch device. General anesthesia was used 
in young children, and when otherwise indicated. All the routine biopsies 
were examined by a pathologist on duty, and by pediatric nephrologists 
responsible for the treatment of the patients. In study II, the biopsies were 
also coded and examined by two investigators without the knowledge of 
kidney function or time aft er TX. Th e histologic fi ndings were graded 
according to the Banff  ’97 criteria [70]. In addition, a more extensive 
scoring table was used [45] and the chronic allograft  damage index (CADI) 
[197] was calculated. 
7.3.6 Serum concentration of methylprednisolone and cortisol, 
and glucocorticoid bioactivity
Th e sixteen patients who participated in Study IV, received 0.3 mg/kg of 
MP orally (tablet Medrol, Pfi zer, Ascoli Piceno, Italy) in the morning of the 
study day. MP or any other GC medication was not taken on the study day, 
or on the day before. All other prescribed medication was allowed to be 
taken normally, and food or liquid intake was not restricted. Blood samples 
for serum methylprednisolone (S-MP) and serum cortisol (S-cortisol) 
concentration, and serum glucocorticoid bioactivity (GBA) analyses were 
drawn on the day the patients would normally take their MP dose. Timed 
blood samples were drawn using an intravenous cannula before (0) and 
1, 2, 3, 4, 6 and 8 hours aft er administration of MP. Serum was separated 
into two tubes, which were stored at – 70ºC until analysis. 
S-MP and S-cortisol were determined using ionspray-tendem mass 
spectrometry with the use of PE SCIEX API 300 LC/MS/MS system 
(Sciex Division of MDS Inc, Toronto, Canada) using dexamethasone as an 
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internal standard. Th e quantitation limit of the method was 2.5 ng/ml for 
both MP and cortisol. 
GC eff ect at the target cell level (bioactivity) has been investigated 
by a recombinant cell bioassay, measuring GR-dependent reporter gene 
(luciferase) activity elicited by human serum. In the assay, mammalian 
cells (COS-1) were transfected with a mix of plasmids containing DNA of 
human GR, luciferase reporter and a steroid receptor coactivator (ARIP3). 
Aft er transfection the cells were incubated with human serum, and the 
cell lysates were measured for ß-galactosidase and luciferase activities 
[198]. Glucocorticoid bioactivity (GBA) has been found to be increased in 
asthmatic children receiving inhaled GC therapy [198] as well as in cord 
plasma of preterm infants exposed to antenatal betamethasone regimen 
[199]. Suppression of GBA has been reported to relate to administration 
of mifepristone in women requesting emergency contraception [200]. 
Th eoretically, measuring GBA may off er some advantages over the 
conventional methods for measuring serum steroids. For example, the 
diff erent affi  nities of synthetic glucocorticoids to GR are revealed by GBA, 
and the bioassay is independent of the drug being used. In this study, serum 
GBA was determined using the bioassay, and the results were expressed in 
nmol/L (nM) cortisol equivalents.   
S-MP was 0 ng/mL in all patients on the study day before administration 
of MP. Accordingly, GBA at time t =0 refl ected the endogenous S-cortisol. 
Aft er administration of MP, GBA levels accounted for both, endogenous 
S-cortisol and exogenous S-MP. Linear regression equation at t=0 was 
calculated for cortisol-induced GBA, and the equation was applied to 
estimate the cortisol-induced fraction of GBA (GBACortisol) at t =1 – 8. GBA 
exceeding that caused by cortisol was calculated by subtracting GBACortisol 
from the measured total GBA. Aft er ingestion of MP, most of the total GBA 
consisted of excess GBA, and the proportion of GBACortisol was marginal. 
In multiple regression analysis, S-MP was the only signifi cant parameter 
explaining the total GBA. Consequently, total GBA was used in calculations, 
and “GBA” in text and tables refers to total GBA, unless otherwise stated.
7.3.7 Data collection
Medical records of the perioperational hospital stay (study I-IV), and of 
control visits thereaft er (study II-IV) were reviewed. Data were collected 
and analyzed retrospectively in all studies. Information was collected 
concerning clinical and laboratory data, fi ndings of FNAB and core needle 
biopsies, and medication, with special emphasis on immunosuppression. 
7.3.8 Statistical analysis
Th e numerical results are generally expressed as mean ±1 standard 
deviation (SD). Unpaired t-test was used for comparison of continuous 
parametric data. Analysis of variance (ANOVA) was used for comparison 
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of more than two groups. Pearson’s correlation coeffi  cient, and simple and 
multiple regressions were used for analysis of a linear relationship. Logistic 
regression was used for non-parametric data. A contingency table was 
used for comparison of nominal data, with either Fisher’s exact test or the 
χ2 (chi-square) test for more than two groups. A p-value of less than 0.05 
was considered to imply statistical signifi cance. All statistical analyses were 
performed using StatView by SAS Inc soft ware.
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8. RESULTS
Triple medication with CsA, AZA and MP has been the cornerstone of 
immunosuppression in Finnish pediatric renal TX patients for over 
two decades. Although the basic protocol is common for all patients, 
individualized adjustments are needed for optimal outcome. Individualized 
management of immunosuppression began in 1988 with calculation of 
recommended CsA doses for each patient already before TX. In order 
to prevent decline in GFR during the fi rst years aft er TX, screening for 
subclinical rejection by early protocol biopsies was initiated in 1999. As it 
became evident that the CsA trough level monitoring may not be suffi  cient 
due to individually variable pharmacokinetics, the C2 monitoring was 
included in the routine management of CsA therapy in 2001. Although 
very useful in maintenance immunosuppression as well as treatment of 
AR steroids are notorious for numerous adverse eff ects. To explore steroid-
related weight gain and growth retardation, a subgroup of pediatric renal 
TX patients was investigated for steroid exposure in 2004.
8.1. Individualized cyclosporine dosing (I)
Individualized CsA dosing during the post-TX hospitalization in 1988-
1998 was analyzed in study I. Based on a pre-TX pharmacokinetic study, 
a recommended CsA dose was calculated for 65 patients (conventional 
formulation in 54 and microemulsion formulation in 11 patients), on an 
average 9.5 months before TX. In the pre-TX study, bioavailability was better 
in patients who received the microemulsion formulation than in those who 
received the conventional formulation (40±13 vs. 24±10%). Accordingly, 
the calculated predicted dose was lower for the microemulsion than for the 
conventional formulation (11.8±8.2 vs. 19.8±10.3 mg/kg/d). Th e variability 
in the predicted doses was age-dependent, the dose recommendations 
being highest for the youngest patients (22.9±10.4, 20.6±9.6 and 10.5±5.1 
mg/kg/d in patients <2, 2–8 and >8 years of age, respectively; p<0.05). 
Data on administered CsA doses was collected for three weeks aft er TX. 
Th e conventional formulation doses were higher than the microemulsion 
doses, and the youngest children received higher doses than the older 
ones, in concordance with the pre-TX pharmacokinetic studies. Th e 
administered doses were on the average very close to the predicted doses 
(Figure 6). Mean deviation from the predicted dose was 0.2, 0.2 and 1.5 
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TX, respectively. In multiple regression analysis the predicted dose and 
patient age were signifi cant parameters explaining on the average 60% of 
the variability in the administered doses. Th e predicted dose explained the 
administered doses best in patients aged 2–8 years. Great variability was 
found in the predicted doses, especially in the youngest age group (Figure 
6). Th e calculated predicted dose deviated more than 25% from the average 
in the age-group in 60% of the patients. When these patients were analyzed 
separately, the predicted dose explained on the average 66% of the variation 
in the administered doses (72% in patients <2 years of age).
Figure 6. Predicted dose in the pre-TX pharmacokinetic study and actually 
administered CsA doses during 1st, 2nd, and 3rd week aft er renal TX in 65 pediatric 
patients in 1988–1999, divided into three groups according to age at TX: 
< 2 years (n=20):  = mean predicted dose, ● = mean administered dose.
2–8 years (n=24):  = mean predicted dose, ■ = mean administered dose. 
>8 years (n=21):  = mean predicted dose,  = mean administered dose.
– = ± 1 SD, X = minimum /maximum in all age-groups.
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Th e targeted B-CsA trough levels were reached on the average aft er the 
fi rst week post-TX. Th e average B-CsA was lower in patients <2 years of 
age than in the older ones. Also, patients who received the conventional 
formulation of CsA had lower B-CsA than those who received the 
microemulsion formulation (Table 4). 
Table 4. B-CsA trough concentration§ in 65 pediatric patients three weeks after renal 
TX in 1988–1998.
Days post-TX
1–7 8–14 15–21 
Age Conv* Microem† Conv* Microem† Conv* Microem†
<2 216±99 239±57 302±63 428±76 313±89 421±52
2–8 263±82 276±53 384±133 403±58 376±118 413±75
>8 282±97 372±127 375±84 419±73 336±108 386±46
§(mean± 1 SD; μg/L)
*Conventional and †Microemulsion formulation of CsA.
8.2 Subclinical rejection and graft function (II)
Graft  function and histology in 24 patients treated according to the revised 
protocol (study group) in 1999–2001 were compared with 35 historical 
controls in 1995–1999. Th e study group and historical protocols are 
summarized in Table 5. One patient in the study group died one month aft er 
the TX in septic infection and multiple organ failure. Another patient in the 
study group died four months aft er TX as a result of recurrent nephrotic 
syndrome, severe rejection, surgical and infectious complications. None of 
the control patients died. 
Table 5. Immunosuppression and follow-up protocol during 18 months after renal 
TX in study group (1999–2001) and in historical control patients (1995 –1999). 
Study Group Historical Controls
Initial 
immunosuppression
CsA, AZA, MP (daily) 
+ Basiliximab induction CsA, AZA, MP (daily)
GFR  At discharge, 3, 6, 12 and 18 months post-TX
At discharge, 6 and 18 
months post-TX
Histology 3 and 18 months post-TX 18 months post-TX
Immunosuppression
aft er 3 months Individualized 
MP (alternate day), tapering 
of CsA and AZA
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Th e historical control patients experienced more early AR episodes than 
the patients treated according to the revised protocol (Table 6). One 
patient in the study group and three in the control group required dialysis 
early aft er TX. Th ree graft s were lost in the control group 4.5, 9 and 16 
months aft er TX, and none in the study group (excluding the deceased 
patients). Twenty-three patients treated according to the revised protocol 
were studied for graft  histology three months aft er TX. Signs of AR were 
found in 43% of the biopsies, and all but one of them were subclinical. Th e 
severity of immunoactivation was graded as borderline in three patients, 
and IA or more (according to Banff  ‘97 classifi cation) in the rest of the 
patients. Early AR did not correlate with the histological fi ndings at three 
months. 
Table 6. Early AR after renal TX in patients treated according to revised protocol 





No of AR (per patient) 9 (0.38) 43 (1.23)
Number of patients with:    1 AR 7 (33%) 14 (40%)
                                 2 or more AR 1 (4%) 12 (34%)
Average day (post-TX) of 1st AR 26* 14*
Average TCI in FNAB 1.8* 2.2*
*p<0.05
Five patients with IA or more severe histological fi ndings, and one patient 
with borderline changes and declining graft  function three months aft er TX 
received AR treatment with MP, and continued daily dosing of maintenance 
MP. One patient with declining GFR was suspected for AR and received 
MP treatment, although graft  histology proved normal. Six patients with 
borderline or IA changes (one patient with CI chronic changes) together 
with good graft  function three months aft er TX did not receive treatment for 
AR but continued on daily dosing of maintenance MP. Based on the severity 
of the histological fi ndings, history of AR, responsiveness to treatment, 
and graft  function, the baseline immunosuppression was modifi ed in 
six patients at three months – CsA was replaced with Tac in three, and 
AZA was replaced with MMF in three patients. Th ree more patients in 
the study group received other than the standard immunosuppression 
(e.g. cyclophosphamide, ATG). In the control group, four patients (11%) 
received other than the standard immunosuppression. AR was found only 
in a few patients 18 months aft er TX whereas chronic changes were more 
common. CAN was found more oft en in the control patients than in the 






















Study < 2 yrs
Control  < 2 yrs
p<0.05 
Table 7. Histology according to Banff ’97 classifi cation in protocol biopsies 18 






Acute changes  
Normal 15 (88%) 26 (87%)
Borderline or more 2 (12%) 4 (13%)
Chronic changes  
Normal 12 (71%) 16 (53%)
C2 4 (24%) 12 (40%)
C2 1 (6%) 1 (3%)
C3 0 1 (3%)
Graft  function was better in the study group than in the control patients. 
Th e diff erence increased with time and was most evident in the youngest 
patients (<2 years of age) (Figure 7). Serum creatinine concentrations were 
also signifi cantly lower in the study than the control group (64±41 vs. 
88±42 μmol/L in all patients, and 49±18 vs. 68±34 μmol/L in patients <2 
years of age, respectively) 18 months aft er TX. However, this diff erence was 
evident already at discharge from the hospital, refl ecting more delayed graft  
function in the control group. CAN was related to lower graft  function 18 
months aft er TX (p=0.02). Also, patients who experienced no rejections 
had better GFR at 18 months in comparison to those who were treated for 
rejection, although the diff erence was not signifi cant. 
Figure 7. Glomerular fi ltration rate (GFR) during 18 months aft er renal TX in 22 study 
group patients in 1999–2001, and in 35 control group patients in 1995–1999. Patients 
under two years of age at TX are shown also separately for both groups.  
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8.3 Cyclosporine monitoring (III)
CsA two-hour post-dose monitoring was included in the routine 
protocol aft er renal TX in pediatric patients in 2001. Data on C2 and 
C0 concentrations during post-TX hospitalization were collected for 47 
patients until 2006. C2 was determined on 1–5 day intervals aft er the 
patient had been switched to oral administration of CsA. CsA therapy was 
initiated intravenously in all patients but switched to oral administration 
aft er 2 days in 53% of the patients, and by the 5th postoperative day in 83% 
of the patients. Overall 547 and 916 values of C2 and C0, respectively, were 
available, concentrating on days 6 to 17 aft er TX. 
Patient and graft  survival was 100%, but two patients required dialysis 
early aft er TX due to delayed graft  function. CsA was included in the initial 
immunosuppression in all patients but replaced with Tac in two patients 
three weeks aft er TX. Th ese two patients were excluded from analyses. CsA 
was replaced with Tac in four more patients aft er discharge from hospital 
but before the three month control. Th ese patients were included in the 
analyses covering the post-TX hospitalization period. CsA was started 
with a pharmacokinetically determined individual dose three times daily 
in all patients <8 years of age, and also in many of the older patients but 
switched to two daily doses before discharge from the hospital. Patients who 
received three or two daily doses of CsA invariably throughout their stay 
in hospital, were categorized as TID or BID patients, respectively. Th ose 
patients who initially received three oral doses daily, but were switched to 
two doses aft er no more than fi ve days, were categorized as BID patients, 
and C2 data on the 1–5 days on TID was omitted from the analyses. Four 
patients were switched to BID aft er more than fi ve days on TID, and were 
thus excluded from analyses covering the post-TX hospitalization period. 
Twenty-nine patients (71%) were categorized as TID and twelve patients 
(29%) as BID. Th ree months aft er TX, all patients ≥8 years of age were on 
BID, and the younger patients were on TID dosing.  
Fourteen (29%) AR episodes were treated in 13 patients on the average 
15 days aft er TX. Th e patients who experienced AR did not diff er from 
those who remained rejection-free with respect to age, gender, pre-TX 
diagnoses or donor source (Table 8). Seven AR episodes occurred early 
(days 7–9) aft er TX and the remaining seven later (days 15–28). Th ese AR 
episodes are referred as “early” and “late”, respectively, in the following text 
and pictures. Nine AR episodes were diagnosed in TID patients, and fi ve in 
BID patients (p=ns).  FNAB was used routinely to diagnose AR, and a core 
needle biopsy was obtained in fi ve patients (AR confi rmed in 4 patients 
and 1 patient had normal histology). Th e patient with normal histology 
received treatment for vascular rejection, while all other AR episodes 
resolved aft er a standard treatment with MP.
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Table 8. Patient characteristics in Study III shown separately for patients without 






Male/Female (n) 18/16 10/3 0.19
Pre-TX diagnosis (n)
             NPHS1
             Polycystic kidneys
             Urethal valve
             Nephronphthisis












Age at TX (years)







CD/LRD (n) 31/3 10/3 0.33
Cold ischemia time (hours) 18.3±6.3 22.0±4.2 0.10
BID/TID (n) 7/20 5/9 ns
Re-TX (n) 1 0 -
Th e coeffi  cient of variation in C2 during the post-TX hospitalization ranged 
from 0.17 to 0.59 from one patient to another, refl ecting substantial day-to-
day intra- and inter-patient volatility. No correlation between C2 and C0 
was observed (R2=0.03). C2 and C0 levels in patients who experienced AR 
were recorded for three days preceding the episode (pre-AR). Th e average 
pre-AR C2, C0 and diurnal abbreviated AUC was then compared with that 
in non-rejecting patients. Average C2, C0, and diurnal abbreviated AUC 
over days 5–9 and 13–17 aft er TX in the non-rejecting patients were used 
as reference levels for “early” and “late” AR, respectively. Th e C2 levels in 
the non-rejecting patients were slightly higher than the pre-AR levels in 
patients with “early” or “late” AR. C0 was signifi cantly higher in rejection-
free patients than the pre-AR C0 in patients with “late” AR. Th e pre-AR 
abbreviated AUC was slightly, although not signifi cantly, lower in the 
“early” and “late” AR patients than in the rejection-free patients (Figure 8). 
In logistic regression analysis, the only signifi cant parameter explaining 
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Figure 8. Average a. two-hour post-dose (C2), b. through (C0) concentration, and c. 
diurnal abbreviated AUC three days before diagnosis of “early” or “late” acute rejection  
(AR) compared to patients with no AR in days 5–9 and 13–17 aft er TX, respectively. 
Th e patients on two (BID) and three (TID) daily doses of CsA are shown separately. 
(Th e error bars denote  ±1 SD)
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Th e BID patients had higher C2 and lower C0 than the TID patients early 
(days 5–9) aft er TX (1558±385 vs. 1345±300 μg/L; p=0.09, and 313 ±47 
vs. 310±91 μg/L; p=ns, respectively), and more signifi cantly later (days 
13–17) aft er TX, when a pharmacokinetic steady-state may be expected to 
be reached in most patients (1769±382 vs. 1284±250 μg/L; p<0.0001, and 
340±50 vs. 396±62 μg/L; p=0.02, respectively). Th e diurnal abbreviated 
AUC was higher in TID than BID patients early (p=0.07), and more 
signifi cantly later aft er TX (p<0.001).  
C2 and C0 data was available in 40 patients three months aft er TX. 
Twenty-two (55%) of these patients had normal histology and 18 (45%) 
had acute rejection changes (Banff  borderline or more) in the 3-month 
protocol biopsy. Rejection changes in the biopsy were not related to AR 
episodes during post-TX hospitalization. C2 levels three months aft er TX 
did not diff er in patients with normal histology or rejection changes in 
the protocol biopsy. However, trough levels, and diurnal abbreviated AUC 
in patients with normal histology were slightly higher than in those with 
rejection (Figure 9). C2 or C0 levels during post-TX hospitalization were 
not related to graft  histology three months aft er TX.
GFR at discharge from hospital was slightly but not signifi cantly better 
in those patients, who did not experience acute rejections (76±34 vs. 66±23 
ml/min/1.73m2; p=0.34). In regression analysis, GFR at discharge was not 
related to C2 or C0 levels, or diurnal abbreviated AUC. Th ree months aft er 
TX, GFR was not signifi cantly diff erent in patients with normal histology 
than in those with rejection changes in protocol biopsy (66±25 vs. 64±17 
ml/min/1.73m2, respectively; p=ns). GFR was not correlated with C0 or C2 

































Figure 10. Cyclosporine a. two-hour post-dose (C2), and b. through (C0) concentra-
tion, and c. diurnal abbreviated AUC three months aft er TX in patients with normal  
histology or acute rejection changes (Banff  borderline or more) in protocol biopsy. Th e 
patients on two (BID) and three (TID) daily doses of CsA are shown separately. 




















































































8.4 Methylprednisolone exposure and adverse effects (IV)
Eight-hour AUCs of MP, serum cortisol and serum GBA were analyzed 
in sixteen voluntary stable renal TX recipients, and great interindividual 
variability was observed (Figure 10). Suppression of endogenous cortisol 
secretion by administration of MP was seen as prompt decline in S-cortisol 
levels (Figure 10c). S-MP was linearly related with GBA (Figure 11), and 
the best correlation was found at six and eight hours post-dose (R2 =0.73, 
79 respectively; p<0.001). 
Figure 10.a. Serum methylprednisolone (S-MP), b. serum GBA, and c. serum cortisol  















































Figure 11. Linear regression of GBA and S-MP one to eight hours aft er oral adminis-
tration of 0.3 mg/kg of MP in 16 stable renal TX patients.
At the time of the study (8.0±4.1 years aft er TX), all patients received 
low alternate day doses of maintenance MP (5.3±3.3 mg, which equals 
0.13±0.04 mg/kg). Th e MP doses received earlier varied slightly depending 
on history of rejections. Twelve months aft er TX, the alternate day MP dose 
had been 0.29±0.08 mg/kg, and at discharge from hospital the daily dose 
had been 0.37±0.06 mg/kg. Six patients had gained excess weight (>10% 
increase in relative weight for height) within twelve months aft er TX, and 
three other patients later aft er TX. At the time of excess weight gain, all 
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patients had been >5 years of age. Average patient height at the time of 
the study was – 1.4±0.8 SDS, and change in height from TX to study date 
showed an average positive catch-up growth of 0.2±0.9 SDS. 
Accelerated weight gain aft er TX correlated with MP-AUC (R2 =0.63, 
p<0.001). GBA-AUC was not linearly related to weight gain, but GBA at t =6 
hours was positively correlated with weight gain (R2 =0.54, p=0.001). Since 
weight-related test-doses were used in this study, obese patients received 
larger doses in absolute terms than those with normal weight for height. 
However, the absolute MP dose was only weakly correlated with weight 
gain (R2 =0.22, p=0.06), and MP dose was excluded by stepwise regression 
procedure in explaining obesity aft er TX. MP-AUC and patient age at TX 
remained the only signifi cant variables (R2 =0.84, p<0.0001). To further 
eliminate the potentially confounding eff ect of current obesity, patients 
were grouped according to absolute weight (in kilograms). MP-AUC and 
GBA-AUC were signifi cantly higher in the obese than non-obese patients 
with similar weight (Figure 12). No correlation was found between early 
AR (when increased steroid doses were used) and weight gain aft er TX.
Figure 12. a. Methylprednisolone AUC (MP-AUC) and b. glucocorticoid bioactivity 
AUC (GBA-AUC) in the obese (weight for height >10%) and non-obese patients 
grouped according  to absolute body mass at the time of the study.
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A linear relationship was observed between growth and MP-AUC 
(Figure 13). GBA-AUC was not linearly related to growth but GBA at t =6 
hours was negatively correlated with change in height (R2 =0.38, p<0.05). 
Blood glucose level, serum lipids, bone mineral density, serum creatinine 
or GFR were not linearly related to MP-AUC or GBA-AUC. Patients with 
normal graft  histology in a recent biopsy had slightly but not signifi cantly 
higher MP-AUC than those patients with rejection changes or CAN. 
Patients with suboptimal graft  function (GFR <60 ml/min/1.73m2, n =7) 
had higher GBA-AUC, most clearly at t =3–6 hours, than those with good 
function (p<0.05), with no diff erence in MP-AUC.   
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Figure 13. Linear regression of change in height (SDS) from TX to study date and  
methylprednisolone (MP) AUC in 14 stable renal TX patients.
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9. DISCUSSION
A well-functioning kidney transplant may fully rehabilitate a patient 
with ESRD. However, a poorly functioning graft  and intensive use of 
immunosuppressive medication are associated with serious morbidity 
and mortality. Improvements in post-TX care and the development of 
more potent immunosuppressive agents have led to a decrease in the 
incidence of AR and increase in short-term graft  survival. As the potent 
immunosuppressive agents remain non-selective, the risk of post-TX 
infections and malignancies exist [155]. Th e goal of pediatric TX is good 
quality of life for decades, and therefore, careful judgment of adequate 
immunosuppression is required for each patient. 
Etiology of ESRD in pediatric patients in Finland is heterogeneous, 
although the most common cause is NPHS1. Consequently, the proportion 
of very young children is relatively high among renal TX recipients, 
which may be considered a risk factor for post-TX complications and 
rejections. Th e age-dependent diff erences in pharmacokinetics and 
immune responsiveness should be incorporated in elaboration of 
immunosuppressive protocols. Added to that, great individual variability 
is inherent to many immunosuppressive agents. Triple medication with 
CsA, AZA and MP has remained the backbone of immunosuppression in 
the Finnish patients. To avoid the potential long-term adverse eff ects, the 
newest, rather potent immunosuppressive agents have not been included 
in the baseline protocol but used on individual basis. Pharmacokinetics, 
graft  function, and histology are employed to assess the required level of 
immunosuppression in each patient.
9.1 Cyclosporine dosing and monitoring (I, III)
Even aft er introduction of the microemulsion formulation of CsA, 
great inter- and intraindividual variability is observed in CsA blood 
concentrations, or to put it the other way round, in dosing requirements 
to achieve a target concentration. Patients receiving the conventional oil-
based formulation and patients receiving the microemulsion formulation 
of CsA were included in Study I. Th e numerical results must be interpreted 
separately for both groups, but the pharmacokinetic principles and analyses 
apply equally for both groups. In the pre-TX pharmacokinetic studies, 
the predicted doses in patients <2 years age were two-fold greater than in 
patients >8 years of age (Figure 6), in accordance with faster elimination of 
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CsA in young children [194]. Th e youngest patients, accordingly, received 
signifi cantly higher doses of CsA aft er TX than the older children. Very 
large variability was observed in the predicted and administered doses. 
Patient age and the pharmacokinetically predicted dose were important 
determinants of the administered doses. Th e actually administered doses 
were best predicted by the recommended dose in those patients who 
required clearly lower or higher doses of CsA than the average patient 
of the same age group. Identifi cation of these patients without a pre-TX 
pharmacokinetic study would be diffi  cult. Using a standard starting 
dose in all patients may thus result in too low or high initial B-CsA 
concentration, and bear the risk of early acute rejection or CsA toxicity. 
However, calculation of the recommended doses is based on a trough level 
target, which may not be optimal in all patients. Trough level monitoring 
of CsA has proved insuffi  cient in refl ecting drug exposure and predicting 
outcome. Instead, the two-hour post-dose concentration has been shown 
to correlate with AUC. Currently, validation studies for C2 in children are 
lacking, and conclusive target levels are yet to be defi ned. 
 Abbreviated AUC based on C0 and C2, has been shown to correlate 
with CsA exposure [201, 202], and therefore, optimizing C0 and C2 
may be expected to result in appropriate exposure. However, the true 
shape of an individual curve may still not be captured by the two-point 
estimation, thus bearing the risk of underestimation in slow absorbers and 
exaggeration in fast metabolizers, when aiming at uniform AUCs [203]. 
On the other hand, the maximum immunosuppressive eff ect occurring 
at peak concentrations, usually during the fi rst two hours post-dose may 
be clinically more important than the complete exposure [100], thus 
emphasizing C2 as the prognostic parameter. 
Young children metabolize CsA faster than school-aged and older 
children [91], and therefore, three daily doses instead of two, may be 
justifi ed. Diff erent dosing intervals may result in disproportionate AUC 
exposure with equal C2 targets for BID and TID patients. Approximately 
30% lower C2-target in TID patients may be anticipated [204] when a 
uniform diurnal AUC is the objective. At the same time, this approach 
would compromise the peak concentrations in TID patients and may 
result in increased AR. In this study, C2 was clearly higher and C0 lower 
in BID than TID patients, but the diurnal abbreviated AUC was higher in 
TID patients. However, it may be possible that the true pharmacokinetic 
profi les in TID and BID patients diff er in a non-linear fashion, resulting in 
lower than expected diurnal exposure in TID [205]. 
Whether suffi  cient peak concentration or adequate diurnal exposure is 
the optimal target in calcineurin inhibition –based immunosuppression 
is a fundamental question in designing dosing schemes. Th e fi ndings in 
this study are suggestive that high C2 levels may be related to freedom of 
AR, especially during the early weeks aft er TX. However, the through level 
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appeared signifi cant aft er the fi rst two weeks, and also three months aft er 
TX. It may be hypothesized that during the early days aft er TX, when the 
supply of donor derived antigens is abundant, high peak concentrations are 
required to prevent AR driven by direct allorecognition mechanisms. Later 
aft er TX, when indirect mechanisms of allorecognition prevail, adequate 
trough level, and diurnal exposure may become more relevant to guarantee 
suffi  cient baseline immunosuppression.
CsA dosing and monitoring remains a challenge in children. Th e need of 
higher dosing in young children has become evident. In addition to patient 
age, the individually variable pharmacokinetic characteristics should be 
considered in optimizing CsA dosing. Much evidence support C2 as a good 
surrogate marker for CsA AUC, and suffi  cient C2 concentration appears 
to be related to less rejection. However, monitoring CsA therapy without 
knowledge of trough concentration may result in excessive or insuffi  cient 
baseline immunosuppression [206], and potentially to consequent 
toxicity or rejection. Th e better understanding of CsA pharmacokinetics 
and mechanisms of action have provided guidelines for more accurate 
monitoring and dosing, but with some added complexity involved in the 
daily routines. 
9.2 Subclinical rejection and graft function (II)
Graft  function aft er renal TX in the Finnish patients has been relatively 
good. However, children transplanted at <2 years of age, were previously 
found to be at risk for insuffi  cient increase in GFR to compensate for the 
growth of the child. In the youngest children the absolute GFR appeared 
to remain at the level reached 18 months aft er TX [35]. Since a signifi cant 
proportion of the Finnish patients are transplanted at a very young age, there 
has been some reluctance to include the strongest immunosuppressants in 
the routine protocol in fear of the potential long-term risks of increased 
infections, malignancies and diabetes. In an attempt to prevent the 
observed reduction in graft  function, the early immunosuppression was 
slightly enhanced and individualized in all patients 1999 onwards. 
In study II the eff ect of the modifi cation in protocol to AR and graft  
function was compared to historical control patients. Th e study and 
control groups in Study II were comparable with respect to patient age, 
gender, pre-TX diagnoses, cold-ischemia time, and AB/DR mismathches. 
However, some diff erences that may infl uence the outcome of TX were 
found between the groups, and could not be controlled. Th e study group 
included two re-TX patients and a greater number of patients < 2 years of 
age, both of which can be considered risk factors for succesfull TX. On the 
other hand, the number of LRD was higher in the study group, and the 
youngest patients received larger volumes of maintenance fl uids aft er TX. 
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Although not similar, risk factors were found equally in both groups.
Th e introduction of basiliximab induction therapy resulted in lower 
FNAB TCI scores and fewer AR episodes soon aft er TX. Th e AR episodes 
were diagnosed on the average 12 days later than in the historical control 
patients. A probable cause for this delay was the eff ect of basiliximab, which 
increases the early post-TX immunosuppression enough to postpone the 
signs of immunoactivation. Th is bears the inherent risk of AR occurring 
aft er the patient has been discharged from hospital. Th e Finnish patients 
are typically discharged 3 to 4 weeks aft er TX, and hitherto all early AR 
episodes have been diagnosed during the hospitalization period.
Since 1999 a protocol biopsy has been obtained in all patients three 
months aft er TX. All protocol biopsy specimen obtained between 1999 and 
2001 were systematically analyzed, and a subclinical rejection was diagnosed 
in 39% of patients. Th e subclinical rejection was not reliably predicted by 
the early FNAB TCI scores, and thus, not by early acute rejections. Th e 
observed frequency corresponds to the previously published incidence of 
silent immunoactivation of the graft   [170, 171, 207]. Controversy exists 
weather increased baseline immunosuppression reduces the prevalence 
of subclinical rejection [174, 208]. In this study (II), most acute changes 
detected at three months subsided and little CAN developed. In a previous 
study in the Finnish renal TX patients, 30% of the graft s presented chronic 
rejection changes at 18 months [209]. In the present study, histologic 
changes consistent with slight CAN were present in 2 (9%) of the patients 
already three months aft er TX, and the number increased to 29% by the 18-
month surveillance biopsy. Th e prevalence of chronic changes was higher 
(47%) in the historical control patients in the 18-month biopsy. Reduction 
in graft  function 18 months aft er TX was related to graft  histopathology 
both in the historical control patients and the patients treated according to 
the revised protocol.
Reduction in number of ARs, increased fl uid volumes, controlling 
of subclinical immunoactivation and individualized dosing of 
immunosuppressive medication might all have limited the damaging 
immunologic or vascular processes, and thus contributed to the 
improved graft  function in the patients treated according to the revised 
protocol. Th e improvement in GFR was most evident in patients ≤2 years 
of age at TX, which could be signifi cant for the long-term prognosis as 
the potential to compensate for the growth of the child could be better 
preserved in these patients.
9.3 Methylprednisolone exposure (IV)
Th e individual pharmacokinetics may result in variable drug exposure 
when standardized or body weight related dosing schemes are followed 
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[210]. Pharmacokinetic parameters have been reported to relate to the 
immunosuppressive effi  cacy [136, 137] and to clinical side eff ects of 
GCs [138, 211], although with one contradiction [212]. To investigate 
the glucocorticoid milieu in Finnish pediatric TX patients receiving 
chronic GC therapy, two diff erent analytical methods were used and the 
results were compared to GC-related adverse eff ects in a small cohort of 
volunteers. In previous studies, GBA has been found to be increased in 
asthmatic children receiving inhaled GC therapy [198] as well as in cord 
plasma of preterm infants exposed to antenatal betamethasone regimen 
[199]. Suppression of GBA has been reported to relate to administration of 
mifepristone in women requesting emergency contraception [200]. In this 
study (IV), GBA correlated moderately with serum MP concentrations. 
Best correlation between the data obtained using the two methods was 
observed in the serum samples taken six to eight hours post-dose, whereas 
during the earlier hours the values were more diverging. MP is rapidly 
metabolized with a mean half-life of 2–3 hours to inactive compounds and 
to a minor active compound, methylprednisone [213–216]. Renal excretion 
of unchanged MP is minimal. Accordingly, the MP AUC did not correlate 
with the GFR. However, the patients with decreased renal function had 
higher GBA values. It is possible, that in these patients some metabolites 
of MP may accumulate. Th e metabolites (or their deconjugation products 
formed during the assay) might possess GR activating capacity and be 
detected by the GBA assay, thus explaining the convergence of the linear 
relationship between MP concentration and GBA values towards 6 to 8 
hours post-dose. 
In a previous study, GC exposure, rather than dose, was related to 
adrenal suppression and growth retardation in Finnish pediatric TX 
patients [138]. In the present study (IV), MP AUC was related to growth 
inhibition and weight gain aft er renal TX. It is probable that these patients 
with marked GC side-eff ects have been exposed to higher plasma MP 
concentrations over the years aft er TX as compared to their counterparts 
with a similar weight-related dose but smaller AUC. Although body surface 
area related dosing of GCs appears to reduce interindividual variability in 
drug exposure [217], the fi ndings in this study (IV) support monitoring of 
serum MP concentrations to avoid the long-term adverse eff ects.  
All the patients in this study (IV), who had gained excessive weight aft er 
TX were over 5 years of age. Th is could be attributable to the fact that 
parents generally control the diets of young children, whereas school-aged 
children have more freedom in choosing their eating habits. Glucocorticoids 
are known to increase appetite and lipogenesis with a net increase in fat 
deposition [218, 219] and they may increase energy intake [220], although 
there are very few studies in children. Obesity aft er TX has been considered 
a risk factor for dyslipidaemia [221, 222]. In Finnish pediatric renal TX 
patients, mild hyperlipidaemia is a frequent fi nding (47–56%), and the 
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risk for dyslipidaemia increases with older age at TX [50]. Obesity is also 
associated with elevated blood pressure in children [223–225]. Aft er renal 
TX, hypertension is common and associated with multifactorial etiology, 
including immunosuppressive drugs [226]. Taken together, school-aged 
TX patients are encountered with considerable risk for obesity. Th us, 
intensifi ed eff orts should be undertaken towards preventing weight gain in 
this age group of patients receiving GC treatment. 
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10. CONCLUSIONS
As the patient and graft  survival aft er renal TX has improved remarkably 
during the past decades, it has become evident that fi ne-tuning and 
optimization of immunosuppression is imperative for good long-term 
graft  function and quality of life. In this study, the individually variable 
pharmacokinetics of CsA and its clinical implications were analyzed. Th e 
infl uence of controlling subclinical rejection on subsequent graft  function 
was investigated. Also, MP exposure and its association with steroid-related 
adverse eff ects aft er transplantation were analyzed. Th e main fi ndings and 
conclusions of the study were:
CsA pharmacokinetics are highly variable depending on the patient age 1. 
and other individual characteristics. Pre-TX pharmacokinetic studies 
of CsA are useful in predicting individually suitable starting doses aft er 
TX. Th e patients who need signifi cantly higher or lower doses than 
the average of their age-group, appear to benefi t most from a pre-TX 
pharmacokinetic study.
Trough level –based monitoring of CsA results in highly variable C2 2. 
levels, and TID patients have lower C2 and higher C0 than BID patients 
during the post-TX hospitalization. High C2 levels very early aft er TX 
may be protective against AR, but aft er the fi rst few weeks suffi  cient 
trough concentration, or diurnal exposure, may be equally important. 
Th ree months aft er TX, suffi  cient trough level appears to be related 
to normal graft  histology. Optimization of CsA therapy requires 
monitoring of both trough level and C2.
Histopathologic fi ndings in asymptomatic patients with well-3. 
functioning graft s are common. Diagnosis and treatment of these 
subclinical rejections three months aft er TX results in improved graft  
function eighteen months aft er TX, most remarkably in the youngest 
patients. 
Methylprednisolone exposure in pediatric patients is highly variable, 4. 
and is associated with the steroid-related adverse eff ects of weight gain 
and growth retardation aft er TX. Individualized dosing in long-term 
steroid treatment might reduce the related adverse eff ects.   
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